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OxLDL uptake via the CD36 scavenger receptor leads to foam cell formation and is at the 
core of the development of atherosclerosis. One potential protective mechanism against this 
process involves the human macrophage derived anti-oxidant 7,8-dihydroneopterin (7,8-
NP) down regulating CD36. This study characterised CD36 down regulation in the U937 
monocyte-like cell line, and examined a mechanism of action involving MAP kinase 
mediated control of the PPARγ transcription factor.  
Western blot analysis showed that in U937 cells 7,8-NP concentrations up to 150µM down 
regulated CD36 to ~40% of basal levels over 24 hours. The effect seen here was stronger 
than that previously observed with human monocyte derived macrophages (HMDM). The 
oxidised product of 7,8-NP, neopterin, had no significant effect. CD36 levels were able to 
recover after down regulation and neared control levels 24 hours after 7,8-NP removal.  
CD36 protein levels were found to be under control of PPARγ and it was shown that 7,8-
NP likely only has its effect at the transcriptional level, and did not enhance the proteolytic 
removal of CD36. PPARγ contains a MAP kinase binding site which when phosphorylated 
prevents the transcription of CD36. Co-incubation of selective MAP kinase inhibitors 
SP600125 (JNK) and PD98059 (ERK1/2) with 7,8-NP failed to block CD36 down 
regulation. The effect of p38 and NF-κB signalling in CD36 down regulation was 
additionally explored using their inhibitors (SB202190 and BAY 11-7082 respectively), 
but likewise did not block 7,8-NP’s effect. 
The results confirm that in the U937 cell line 7,8-NP can decrease the levels of CD36, and 
that a regulatory pathway involving PPARγ is likely. It is also shown that 7,8-NPs 
mechanism of action does not involve the activation of a MAP kinase cascade 
phosphorylating PPARγ. This points towards a different mechanism of action, possibly 






Cardiovascular disease is a leading cause of death accounting for 16.7 million fatalities 
globally each year (Dahlöf, 2010). A major pathology of cardiovascular disease is 
atherosclerosis, otherwise known as the hardening of the artery wall (Hansson, 2005).  This 
process is characterised by the recruitment of immune cells and the deposition of lipids 
alongside cellular debris within the arterial wall. Over time this leads to the formation of 
atherosclerotic plaques and results in the occlusion of blood flow (Lusis, 2000). 
Cardiovascular disease may manifest as angina, stroke or myocardial infarction (Roger et 
al., 2011). 
Oxidative stress and inflammatory cell death are at the core of the development of 
atherosclerosis. One of the fundamental interactions during this process is the death of 
macrophage cells after exposure to oxidatively modified low density lipoprotein (oxLDL) 
(Moore & Tabas, 2011). Low density lipoprotein (LDL) is a key component of the 
lipoprotein pool that functions in the transportation of lipids around the body. Oxidative 
modification of this particle results in oxLDL which is pro-inflammatory and cytotoxic 
(Berliner & Heinecke, 1996). OxLDL will interact with and be taken up by macrophage 
cells leading to the formation of foam cells (Henriksen, Mahoney, & Steinberg, 1983). 
These foam cells remain within the artery wall and make up a significant part of the 
atherosclerotic plaque (Stocker & Keaney, 2004). The inflammatory properties of oxLDL 
will also contribute to higher levels of oxidative stress within the arterial wall and in doing 
so recruit more macrophages to this location (Park, Febbraio, & Silverstein, 2009). 
The initial step that results in the uptake of oxLDL is mediated by a class of cell surface 
receptors termed scavenger receptors. Cluster of differentiation 36 (CD36) is the scavenger 
receptor most associated with oxLDL triggered cytotoxicity and oxLDL uptake as CD36 
contains motifs on its extracellular portion that allows for recognition and binding of the 
oxidised components of oxLDL (Ohidar, 2010). Mechanisms that are able to decrease 
levels of CD36 are of increasing interest in order to slow the progression of atherosclerosis. 
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One potential mechanism for CD36 down regulation relates to the human macrophage 
derived anti-oxidant 7,8-dihydroneopterin (7,8-NP). The protective role of 7,8-NP against 
macrophage foam cell formation is believed to be two-fold; 1) Its antioxidant activity which 
scavenges any reactive oxygen species (ROS) that may be generated in response to oxLDL 
(Gieseg, Reibnegger, Wachter, & Esterbauer, 1995; Gieseg, Crone, Flavall, & Amit, 2008). 
2) The down regulation of CD36 resulting in a decrease in the amount of oxLDL that is 
taken up by macrophages in the first place (Gieseg, Amit, Yang, Shchepetkina, & Katouah, 
2010).  
This research focuses on the second mode of action and explores how 7,8-NP is able to 
down regulate CD36 expression. By testing the effects of various inhibitors of intracellular 
signalling we explore the mechanism of CD36 down regulation by 7,8-NP, with the aim of 
increasing our understanding of its protective effect in atherosclerosis. Specifically 7,8-
NP’s ability to down regulate the CD36 scavenger receptor and thus prevent foam cell 
formation. 
1.2 Atherosclerosis 
1.2.1 Atherosclerosis and cardiovascular disease 
Atherosclerosis is the underlying process in cardiovascular disease which includes 
coronary heart disease, strokes and peripheral vascular disease. Altogether cardiovascular 
disease accounts for 30% of deaths globally (Santulli, 2013). The progression of 
atherosclerosis is a chronic and complex process. Its development involves endothelial 
dysfunction, arterial inflammation, immune cell recruitment and the thickening of the 
arterial intima through a build-up of cellular debris, lipids, cholesterol and calcium 
deposition (Bobryshev, 2006). Remodelling of the arterial wall results in large occlusions 
known as atherosclerotic plaques that restricts blood flow and reduces oxygen supply. As 
an atherosclerotic plaque progresses the lesion can become unstable and may rupture. Once 
ruptured the plaque will release its contents into the blood stream triggering thrombus 
formation, which if lodged in the small capillary beds, can further restrict or completely 
block blood supply (Falk, 1983). The end result of this blockage may lead to myocardial or 
cerebral infarction depending on the location of the plaque (Hansson & Hermansson, 2011; 
Libby, Ridker, & Maseri, 2002). Many risk factors will influence the likelihood of 
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developing atherosclerosis and its severity. These include an individual’s genetic 
predisposition, along with obesity, age, gender, cigarette and alcohol use, sedentary 
lifestyle, hypertension and the presence of type II diabetes and hyperlipidaemia (Libby et 
al., 2002; Meyer & Schmitt, 2000). 
1.2.2 The stages of plaque progression 
The formation of an atherosclerotic plaque develops over a lifetime and goes through 
several stages (Figure 1.1). Six stages of plaque progression have been identified as 
determined by plaque complexity (Ross, 1995). Plaques found in adolescents are often 
identified as being in stage 1 or 2 of development. Here monocyte infiltration into the 
intimal layer of the arterial wall, along with the presence of plasma-derived lipid, initiates 
the thickening of the arterial wall (Ross, 1986; Stary et al., 1995; Steinberg, 1989). As this 
thickening expands the addition of further lipids and cells, along with cell death leads to 
the development of Type III plaques. Necrotic core formation may then occur in which a 
lipid laden area devoid of cells develops deep within the arterial wall. These plaques are 
classified as being Type IV and can also be characterized by a thin layer of tissue that 
separates the necrotic core from the lumen. This layer will develop into a thick fibrous cap 
in Type V plaques. The final stage of plaque formation involves a more complex structure 
in which calcium deposits and ulceration develop, along with atrial vascular remodelling 





Figure 1.1 The development of an atherosclerotic plaque 
The various stages of atherosclerotic plaque development, depicting the normal artery (1), lipid 
deposition (2), fatty streak formation (3), necrotic core and fibrous cap (4) and plaque rupture 
forming a thrombus (5). Adapted from Cross, 2016. 
 
1.2.3 Lipoproteins and oxidised LDL  
Several theories have been proposed to explain the initial process that leads to the beginning 
of plaque formation including the “Response to injury”, “Response to retention” and the 
“Oxidative modification” hypothesis. A common theme in all these theories is the role that 
LDL and immune cells play in atherosclerotic progression. 
The body’s lipoprotein pool is an important source of lipids, both in normal circulation and 
throughout atherosclerotic plaques (Lusis, 2000). Lipoproteins are not homogenous but 
rather are split into many sub-fractions based on size, density and apolipoprotein content. 
Different lipoproteins have different metabolisms and functional properties (Lewis, 1973). 
The major lipoprotein fraction linked to atherosclerosis is LDL, the dominant cholesterol 
ester carrier in the body (Moore & Tabas, 2011). The clearance of LDL from the circulatory 
system is reliant on the LDL receptor which facilitates its endocytosis into hepatic and 
macrophage cells. Recognition of the LDL by its receptor is based upon several specific 
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amino acid residues located on the apolipoprotein B100 (ApoB100), the primary lipid 
recognition protein on LDL. These residues include lysine, arginine and histidine. 
Oxidative induced degradation of ApoB100 results in its fragmentation forming smaller 
peptides and altering its positive lysine residues. This results in the failure of oxLDL to be 
recognised by the LDL receptor (Esterbauer, Dieber-Rotheneder, Waeg, Striegl, & 
Juergens, 1990; Levitan, Volkov, & Subbaiah, 2010; Obama et al., 2007). Recognition of 
oxLDL instead switches to macrophage scavenger receptors. Here rapid and relatively 
unregulated uptake can occur, resulting in the over accumulation of cholesterol within the 
cell and subsequent differentiation into lipid-laden foam cells (Figure 1.2) (Bobryshev, 
2006; Steinbrecher, 1991). OxLDL will further facilitate extensive cellular damage 
triggering a cellular apoptotic or necrotic response (Katouah, Chen, Othman, & Gieseg, 
2015). Cellular contents (including cellular debris, oxidants, chemotactins and cytokines) 
can then be released into the surrounding environment increasing inflammation. This leads 
to the further recruitment of macrophages and production of oxLDL, culminating in a cyclic 
process. (Libby, Ridker, & Hansson, 2009; Madamanchi, Vendrov, & Runge, 2005). 
1.2.4 Macrophages, foam cell formation and cell death 
Macrophages are immune cells derived from monocytes and are involved in both innate 
and adaptive immunity. Macrophage recruitment to a site of infection enables the body to 
trigger an appropriate response for host defence (Mosser & Edwards, 2008). This may 
include the removal of pathogens and other large molecules, the clearance of damaged cells 
and the production of other chemicals used in immune response. These benefits do not 
always outweigh the consequences in terms of atherosclerosis. Macrophage infiltration has 
been shown to play an important part in all stages of atherosclerotic plaque development 
from the initial thickening of the artery wall to the advanced plaque stage (Nakashima, 
Wight, & Sueishi, 2008). Murine models lacking monocyte-macrophage recruitment 
mechanisms show reduced lipid deposition into atherosclerotic lesions while histological 
studies indicate the presence of macrophages within the lipid-rich areas of the plaque core 
(Potteaux et al., 2011).  
As aforementioned the role of macrophages in atherosclerotic plaque development relies 
on their internalization of oxLDL to form lipid-laden foam cells, ultimately resulting in 
macrophage cell death and deposition into a growing atherosclerotic plaque (Steinberg, 
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2009). Foam cells are characterised by their accumulation of cholesterol esters (CE) along 
with oxidation products similar to those seen in oxidatively modified lipoproteins (Jessup 
& Kritharides, 2000).  Macrophages will accumulate CE and oxysterols when exposed to 
oxLDL (Asmis & Jelk, 2000; Boström et al., 2006; Brown, Dean, & Jessup, 1996). OxLDL 
has been shown to facilitate macrophage death in vitro and is suggested to be able to do 
this also within atherosclerotic plaques (Baird, Reid, Hampton, & Gieseg, 2005; Katouah 
et al., 2015). While the exact mechanisms of this process is disputed, the binding, uptake 
and processing of oxLDL plays a key role in the fate of a macrophage (Steinberg, 2009). 
When modified lipoproteins are taken up by a macrophage they are first transported to 
endosomes and then to lysosomes (Brown et al., 2000; Maor & Aviram, 1994). CE content 
is then hydrolysed into free cholesterol and fatty acids at an acidic pH. As oxLDL uptake 
by scavenger receptors is relatively un-regulated, its uptake leads to the accumulation of 
free cholesterol which can be re-esterified via ACAT leading to a large pool of esterified 
cholesterol within the cytosol. Experimental inhibition of ACAT also causes cholesterol 
accumulation in oxLDL treated cells, resulting in Endoplasmic Reticulum stress, protease 
activation, and apoptosis (Ozcan & Tabas, 2016; Wang et al., 1996). Under standard 
conditions excess cholesterol can be efluxed out of the macrophage through reverse 
cholesterol transport. This process is characterised by CE hydrolysis mediated by a family 
of enzymes with carboxyl ester hydrolase/esterase activity. Cholesterol and also cholesterol 
products are then efluxed out of the macrophage onto high density lipoprotein (HDL) 
particles (Johnson, Mahlberg, Rothblat, & Phillips, 1991) via ATP-binding cassette 
transporters ABCA1 and ABCG1 (Yvan-Charvet, Wang, & Tall, 2010). Yet modification 
of LDL has been shown to inhibit this process resulting in macrophages internalizing higher 




Figure 1.2 The formation of a lipid laden foam cell 
Native LDL enters the atrial intima space and undergoes oxidation by cellular oxidants produced 
by endothelial, macrophage and smooth muscle cells. OxLDL then recruits macrophage 
differentiated monocytes to the site of inflammation. OxLDL uptake via scavenger receptors 
triggers the formation of lipid loaded foam cells. Foam cell death then results in the macrophage 
cellular content spilling into the environment, further propagating inflammation within the intima 
space. 
 
1.3 Plaque initiation theories 
1.3.1 Response to injury theory   
“Response to injury” is an early theory proposed by Ross (1986) to explain the initial 
process of plaque formation. In this model disturbance of vascular homeostasis mediated 
via injury is proposed to initiate atherosclerosis. Suggested triggers include disruption of 
laminar flow and oscillatory shear stress at the arterial bifurcation, infection of the vascular 
wall, along with phagocyte associated myeloperoxidase activity (Malek, Alper, & Izumo, 
1999). Disturbed endothelium loses its ability to vaso-regulate making the affected area 
more susceptible to circulating pro-atherogenic lipoproteins (Malek et al., 1999). 
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Endothelial injury will also recruit immune cells which will release pro-inflammatory 
cytokines leading to the promotion and propagation of the inflammatory response (Wick, 
Knoflach, & Xu, 2004).  Part of this response results in the recruitment of leukocytes to the 
site of inflammation with the aim of resolving stress, promoting healing and can lead to the 
migration and adherence of monocytes to the site of endothelial inflammation. Damage 
caused to the endothelial layer also allows for the penetration of LDL into the arterial intima 
layer where oxidative modification may occur due to the inflammatory environment along 
with the presence of immune cells. These factors can result in foam cell formation and the 
growth of an atherosclerotic plaque. 
1.3.2 Response to retention theory 
Williams and Tabas (1995)  suggested a second “response-to-retention” theory in which 
plaque development is triggered by the diffusion and retention of lipoprotein within the 
sub-endothelial layer of the arterial wall where it binds with high affinity to muscle 
associated proteoglycan chains. A major feature of proteoglycans are long carbohydrate 
side chains of glycosaminoglycan’s (GAGs) covalently attached to a core protein via 
glyosidic linkages. This theory is reliant upon the repeating disaccharide units of the GAGs 
which contain negatively charged sulphate or carbohydrate groups. As the LDL moves 
through the sub-endothelial layer the positively charged lysine groups of ApoB100 are 
attracted to the negatively charged sulphate proteoglycans resulting in the adherence of 
LDL to the GAG matrix (Evanko, Raines, Ross, Gold, & Wight, 1998; Libby et al., 2009). 
Retention and aggregation of lipoprotein within the vascular intima allows for its oxidative 
modification by oxidants formed by vascular cells and macrophages. Modification then 
promotes its uptake into macrophages via scavenger receptors leading to foam cell 
formation. 
1.3.3 Oxidative modification hypothesis 
The oxidative modification hypothesis is also commonly accepted in order to explain the 
initial stages of plaque development. This theory states that LDL particles enter the arterial 
intima layer where they become trapped and oxidatively modified by cellular oxidants 
produced either by endothelial or smooth muscle cells (SMC). These cells produce pro-
inflammatory cytokines, adhesion molecules and chemotactic proteins to promote the 
recruitment and migration of monocytes to the inflammatory area within the intima 
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(Hansson, 2001).  Once activated monocytes can roll via cell adhesion proteins along the 
surface of the lumen endothelial layer triggered by a response to endothelial cell released 
pro-inflammatory signals. As the monocytes move through the area they undergo 
differentiation into macrophages in response to inflammatory cytokines. Macrophages in 
turn will produce oxidants such as superoxide, hydrogen peroxide and hypochlorite via the 
NADPH oxidase and myeloperoxidase complexes respectively, in order to oxidise any 
pathogenic threat. This will additionally cause further lipid and protein oxidation of LDL 
forming oxLDL (Bobryshev, 2006; Libby et al., 2009; Steinbrecher, 1991; Stocker & 
Keaney, 2004). OxLDL can then be taken up by macrophage scavenger receptors forming 
lipid laden foam cells which can then be added to a growing plaque (Lusis, 2000).  
Inflammatory cytokines released during this process also play an important role in the 
destabilization of the plaques fibrous cap increasing the likelihood of plaque rupture. 
Released inflammatory cytokines inrerleukin-1, tumour necrosis factor, CD140 and CD40 
can stimulate an up-regulation of matrix metalloproteinases within macrophages and SMCs 
(Libby & Aikawa, 1998; Mach, Schönbeck, Bonnefoy, Pober, & Libby, 1997). It is these 
enzymes that are in part responsible for the remodelling of the extracellular matrix and the 
degradation of the plaques fibrous cap increasing the chances of rupture (Galis, Sukhova, 
Lark, & Libby, 1994; Geng et al., 1995), Once ruptured debris will form an acute 
thrombosis which may get lodged within the artery blocking or restricting blood supply 
resulting in nutrient deprivation and tissue death. This may often manifest as either a heart 








1.4 Scavenger receptors 
1.4.1 Scavenger receptors 
As previously described the oxidative modification of LDL causing foam cell formation 
and cell death lead to the development of the oxidative theory of atherosclerosis. Part of 
the basis of this theory is the observation that cultured monocytes/macrophages will 
internalise oxLDL much more rapidly than unmodified LDL (Ho, Brown, Bilheimer, & 
Goldstein, 1976). The uptake of oxLDL is mediated via macrophage scavenger receptors. 
Scavenger receptors were first identified on activated macrophages and subsequently found 
to function in cholesterol and lipoprotein metabolism, among other roles, by binding and 
endocytosing a range of modified lipoproteins including oxLDL (Endemann et al., 1993). 
After binding, scavenger receptor-ligand interaction facilities a signalling cascade 
regulating macrophage activation, lipid metabolism, and inflammatory pathways (Ashraf 
& Gupta, 2011). Importantly in terms of atherosclerosis, and unlike the normal LDL 
receptor, scavenger receptors will not be down regulated by intracellular cholesterol levels 
allowing cholesteryl ester accumulation to the point of foam cell formation. OxLDL 
binding has even been shown to result in an upregulation event (D'Archivio et al., 2008). 
As such scavenger receptors are considered to be a major factor in the development of 
atherosclerotic plaques.  
To date many classes of scavenger receptor have been identified and range from class A to 
class G. Some function as multi-ligand receptors while others only recognise specific 
structural motifs (Ashraf & Gupta, 2011). OxLDL is initially recognised by several 
scavenger receptors including the class A scavenger receptor A (SR-A) (Kodama, Reddy, 
Kishimoto, & Krieger, 1988), class B scavenger receptors SR-BI and CD36 (Endemann et 
al., 1993), class D scavenger receptor CD68  (Ramprasad, Terpstra, Kondratenko, 
Quehenberger, & Steinberg, 1996), and the class E scavenger receptor, lectin-like oxidised 
low density lipoprotein receptor-1 (LOX-1) (Yoshida, Kondratenko, Green, Steinberg, & 
Quehenberger, 1998). While in vivo evidence is still lacking for the particular role each 





CD36 is an integral membrane bound multi-ligand scavenger receptor found in a number 
of cells including monocytes/macrophages, platelets, endothelial and smooth muscle cells 
(Asch, Barnwell, Silverstein, & Nachman, 1987; Collot-Teixeira, Martin, McDermott-Roe, 
Poston, & McGregor, 2007; Matsumoto et al., 2000; McGregor et al., 1989; Swerlick, Lee, 
Wick, & Lawley, 1992). CD36 present on the cell surface of macrophages plays a crucial 
role in the progression of atherosclerotic legions from the fatty streak to the necrotic plaque 
due to its ability to recognize, bind and endocytose oxLDL. 
CD36 was first identified as a 88 kDa membrane glycoprotein on monocytes using the 
monoclonal antibody OKM5 (Talle et al., 1983). Later on it was discovered that the 88 kDa 
band was the incompletely glycosylated CD36 located in the Golgi apparatus, whereas the 
fully glycosylated 100kDa band is mature CD36 residing on the plasma membrane (Alessio 
et al., 1996). Further studies examining functional and structural characteristics led to CD36 
being classified as a member of the class B scavenger receptor family. The gene encoding 
CD36 has been identified as being more than 46kb in size and located on the q11.2 band of 
chromosome 7 (Armesilla & Vega, 1994; Fernández-Ruiz, Armesilla, Sánchez-Madrid, & 
Vega, 1993). The gene consists of 15 exons, of which exons 4-13 and parts of exons 3 and 
15 contribute to the protein with exons 1, 2 and 15 making up the 3’ and 5’ untranslated 
regions. 
1.4.3 CD36 structure  
The structure of CD36 consists of a ditopic configuration in which an extracellular domain 
is flanked by two transmembrane and two cytoplasmic domains (Figure 1.3). The extra-
cellular region consists of many N-linked glycosylation sites along with containing a 
hydrophobic domain capable of potentially interacting with the plasma membrane, a 
proline rich region between amino acids 242-333 and several functional domains 
(Greenwalt et al., 1992).  One domain located between amino acids 155 to 183 and is able 
to bind to oxLDL, along with growth hormone releasing peptides, hexarelin, and advanced 
glycated products (Navazo, Daviet, Ninio, & McGregor, 1996; Ohgami et al., 2001; Pearce 
et al., 1998). 
12 
 
The binding of oxLDL to macrophage CD36 occurs via a lipid moiety (Nicholson, Frieda, 
Pearce, & Silverstein, 1995) differing to other scavenger receptors in which binding occurs 
via an apoprotein moiety. Here high affinity binding of oxLDL to CD36 appears to be based 
on the recognition of oxidized phospholipids covalently bound to apoB in oxLDL (Boullier 
et al., 2000). The main structural characteristic related here is a phospholipid with a sn-2 
acyl group incorporating a terminal γ-hydroxy(or oxo)-α,β-unsaturated carbonyl which is 
formed during LDL oxidation (Podrez et al., 2002). A computational modelling study 
undertaken by Doi et al. (1993) showed that the CD36 oxLDL binding domain contains a 
positively charged groove made by a lysine cluster which enables specific interactions with 
negatively charged ligands including oxLDL. Bound oxLDL is then able to be endocytosed 
utilizing a raft mediated pathway seemingly separate from caveolae, caveolin-1 and clathrin 
mediated uptake (Zeng, Tao, Chung, Heuser, & Lublin, 2003) 
Once endocytosed oxLDL brings about important transcriptional changes including the up-
regulation of CD36 expression (Shiffman et al., 2000). Upon stimulation via oxLDL the 
Peroxisome proliferator-activated receptor-γ (PPARγ) is activated via the p38 kinase 
pathway (Zhao et al., 2002) forming a heterodimer with the retinoid X receptor (RXR). 
This PPARγ:RXR complex can then bind to elements in the CD36 promoter leading to 
increased CD36 expression (Tontonoz, Nagy, Alvarez, Thomazy, & Evans, 1998). Various 
kinases have also been shown to be involved in CD36 upregulation. Protein kinase C was 
shown to be part of oxLDL-mediated CD36 up-regulation and PPARγ activation (Feng et 
al., 2000) along with protein kinase B (PKB), in which PKB over expression in 
macrophages increased the CD36 promoter along with a PPARγ element-driven reporter 
gene (Munteanu et al., 2006).  
STAT1 signalling also plays a role CD36 transcription. The ligand 15-
Hydroxyeicosatetraenoic acid (15(S)-HETE) acts via this pathway, and inhibition of 
STAT1 activity significantly decreases the expression of CD36 and subsequent foam cell 
formation (Agrawal et al., 2007). STAT1 activation is mediated by IFN-α, IFN-γ, and 
several other cytokines (Gao, 2005). IFN-γ binding to its receptor triggers a cascade of 
events resulting in the activation of the receptor and receptor-janus kinase proteins. 
Activated STAT1 can then form homodimers which when translocated to the nucleus will 
bind consensus DNA γ-activated sites and promote or repress various target genes 
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Figure 1.3 The structure of CD36 
Structure of CD36 showing the oxLDL binding site located between amino acids 155-183 and the 
various glycosylation sites required for maturation and transportation to the cell membrane. 
Adapted from (Collot-Teixeira et al., 2007) 
 
1.4.4 CD36 in atherosclerosis 
Initial work exploring the role of CD36 in atherosclerosis came from Endemann et al. 
(1993) in which the HEK293 cell line transfected with CD36 subsequently acquired the 
ability to specifically bind oxLDL. Later it was demonstrated that CD36, along with class 
A scavenger receptors, accounted for the uptake of between 75-90% of all acetylated and 
oxidised LDL (Kunjathoor et al., 2002). Looking at a human population Nozaki et al. 
showed that a small subset of the Japanese population whose monocytes lack CD36 had a 
40-50% reduction in the levels of oxLDL binding to human monocyte derive macrophages 
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(HMDM) compared to a normal population (Nozaki et al., 1995). The same levels of 
reduced binding were also seen when CD36 binding sites were blocked by specific 
monoclonal antibodies reducing oxLDL binding to HMDMS by as much as 50% (Nozaki 
et al., 1995), with similar results seen in a separate study using THP-1 cells (Endemann et 
al., 1993).  
The in vivo role of CD36 is human atherosclerotic development has yet to be fully explored 
with most evidence coming from animal models. Mice containing a double knockout of 
ApoE and CD36 are a common model used. Lack of ApoE triggers very high circulating 
levels of cholesterol rich lipoproteins and enables the development of atherosclerotic 
lesions at a much faster rate than wild type populations. After 12 weeks ApoE/CD36 
knockout mice exhibit a 76.5% decrease in aortic lesion size compared to mice only lacking 
AopE, while 60% less oxLDL was internalized in the double knockouts compared to ApoE 
alone (Febbraio et al., 2000). Further evidence for role of CD36 in plaque development 
came when CD36 was reintroduced to knockout mice via a stem-cell transfer, resulting in 
an increased size of the atherosclerotic lesion area (Febbraio et al., 2000). The sum total of 
these and similar publications demonstrates the key role that CD36 plays in oxLDL uptake 
and foam cell formation in atherosclerotic development. 
1.5 7,8-Dihydroneopterin 
1.5.1 GTP, 7,8-Dihydydroneopterin and products 
Interferon-γ (INF-γ) is a dimerized & soluble cytokine critical in both innate and adaptive 
immunity. INF-γ has been reported to be involved in the regulation of over 500 genes (Leon 
& Zuckerman, 2005) and has been associated with both pro- and anti-atherogenic 
properties. One of INF-γ’s role in atherosclerosis relates to the stimulation of the production 
of 7,8-diydrneopterin and neopterin  which have both been detected within atherosclerotic 
plaques and associated with cardiovascular events (Huber et al., 1984; Janmale et al., 2015). 
Neopterin is considered to be a viable marker of plaque stability and atherosclerotic 
prognosis (Liu & Li, 2013), while 7,8-NP has been demonstrated in vitro to have a 
protective role against oxLDL mediated cell death (Gieseg, Leake, et al., 2008). 7,8-NP 
and neopterin belong to the pteridine class of compounds which as a common characteristic 
have a pyrazino-2,3-pyrimidine bicyclic nitrogen containing ring system, and depending 
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on the size of substituent groups can further be described and conjugated or un-conjugated 
(Wachter et al., 1992). Further sub-classification for unconjugated pteridines is determined 
on the corresponding oxidation state composing of the fully reduced tetrahydropterins, and 
the partially reduced dihydroneopterins and aromatic pterins (Oettl & Reibnegger, 2002). 
All members of the pteridine class of compounds are synthesized from a guanosine 
triphosphate (GTP) precursor (Figure 1.4). INF-γ stimulates the first step via the enzyme 
GTP cyclohydrolase 1 which metabolises GTP into 7,8-NP  triphosphate (Werner et al., 
1990). Phosphatase enzymes them hydrolyse 7,8-NP triphosphate to generate 7,8-NP 
(Wachter et al., 1992). Co-stimulation with tumour necrosis factor-α (TNFα), 
dexamethasone or LPS has also been demonstrated to enhance synthesis although not as 
strongly as INF-γ (Werner-Felmayer et al., 1995; Werner-Felmayer et al., 1990). 
Breakdown of 7,8-NP after reaction with oxidant species will form neopterin, 7,8-
dihydroxanthopterin and xanthopterin. 
 
Figure 1.4 The biosynthetic pathway of 7,8-NP and its reduced products 
The biosynthetic pathway of 7,8-NP involves the conversion of GTP to 7,8-dihydroneopterin 
triphosphate (7,8-DNT) catalysed by GTP cyclohydrolase-I (GCH-I). Accumulation of 7,8-DNT in 
cells of a myelocytic origin drives the dephosphorisation of 7,8-DNT to 7,8-NO due to insufficient 
6-pyruvonyltetrahydropterin synthase (PTPS). Alternative cells with functional PTPS will drive 
tetrahydrobiopterin formation. Breakdown of 7,8-NP after reaction with oxidant species will form 
neopterin, 7,8-dihydroxanthopterin and xanthopterin. Adapted (Dántola, Vignoni, Capparelli, 
Lorente, & Thomas, 2008; Fuchs et al., 2009) 
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1.5.2 7,8-NP as an antioxidant 
The atherosclerotic plaque is a site of chronic inflammation as indicated by the high number 
of immune cells such as macrophages, and the presence of various inflammatory markers. 
Macrophage cells can release a range of oxidizing agents including superoxide, hydrogen 
peroxide, lipid peroxides, lipoxygenases and possibly hypochlorite, which are all known to 
contribute to the production of oxLDL (Gieseg, Leake, et al., 2008). While the oxidative 
theory of atherosclerosis has come under some criticism due to the inability of various 
antioxidant intervention trials to exhibit protection, these have focused on ascorbate and 
tocopherol which are tightly controlled in vivo and at high levels can act as pro-oxidants 
(Kontush, Finckh, Karten, Kohlschütter, & Beisiegel, 1996; Podmore et al., 1998). Reduced 
pterins, such as 7,8-NP, have also been shown to act as antioxidants and are produced by 
macrophage cells in the atherosclerotic plaque. 7,8-NP has been demonstrated to have a 
protective effect with in vitro studies showing its ability to interfere with LDL oxidation 
(Gieseg et al., 1995), reactive oxygen species (ROS) mediated reactions (Oettl, Greilberger, 
Dikalov, & Reibnegger, 2004) and free radical damage including from hydroxyl and 
peroxyl radicals (Duggan, Rait, Platt, & Gieseg, 2002) 
7,8-NP is a scavenger of superoxide and peroxyl radicals generated via 2,2’-azobis-2-
methyl-propanimidamide dihydrochloride (AAPH) (Oettl et al., 2004) while also reacting 
with hydrogen peroxide and chloramine-T (Weiss et al., 1993). The reaction rate of 7,8-NP 
with AAPH derived peroxyl radicals which nears the rate of diffusion makes it a very good 
inhibitor of this oxidation pathway (Duggan, Rait, Gebicki, & Gieseg, 2001). 7,8-NP has 
also been shown to inhibit oxidation of the polyunsaturated omega-6 fatty acid linoleate via 
AAPH and the formation of diene on LDL particles during both AAPH- and copper-
mediated oxidation of LDL (Gieseg et al., 1995). Another biologically relevant 
experimental system showed a 7,8-NP antioxidant effect in protecting bovine serum 
albumin from AAPH–mediated oxidation (Duggan et al., 2001). 
7,8-NP causes a reduction in erythrocyte haemolysis induced by HOCl, H2O2 and AAPH 
treatments (Gieseg, Maghzal, & Glubb, 2001; Y.-t. T. Yang, Whiteman, & Gieseg, 2012). 
Complete protection was observed in the presence of AAPH and partial protection (40%) 
in the presence of H2O2 (Gieseg et al., 2001). 7,8-NP has also been reported to protect 
against lipid hydroperoxide formation and protein oxidation (Gieseg et al., 2001). 
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Additional studies confirmed this effect of 7,8-NP in which protein hydroxide and lipid 
peroxide formation on LDL was slowed in HMDM and THP-1 cells (Firth, Crone, Flavall, 
Roake, & Gieseg, 2008). 
Further studies into protective roles of 7,8-NP have shown its ability to protects cells of 
myelocytic origin from the cytotoxic effects of oxLDL. It has been found that in monocyte 
like THP-1 and HMDM cells oxLDL formation was fully inhibited with only micro-molar 
concentrations of 7,8-NP (Gieseg & Cato, 2003), while a separate study showed that 7,8-
NP protected U937 cells from the cytotoxicity of oxLDL (Baird et al., 2005). This 
protective role is thought to occur via the use of 7,8-NP’s antioxidant properties to scavenge 
any ROS that may be generated in response to oxLDL.  
1.5.3 Antioxidant down regulation of CD36 
Besides 7,8-NP’s antioxidant properties a second mode of protection is hypothesised to 
occur via the down regulation of CD36 itself, preventing oxLDL uptake and foam cell 
formation (Figure 1.5). In HMDM cells the addition of 7,8-NP triggered the down 
regulation of the 100-kDa form of CD36 and partial reduction of the immature intracellular 
88-kDA form, while also reducing the levels of reactive oxygen species (S. Gieseg et al., 
2010). 7,8-NP is not the only antioxidant known to down regulate CD36 expression. α-
tocopherol (Vitamin E) is well known as a lipophilic antioxidant and has been shown to 
inhibit oxLDL uptake by the down regulation of CD36 mRNA and protein expression 
(Ricciarelli, Zingg, & Azzi, 2000). Yet the same effect is not seen with given β-tocopherol 
or probucol thus ruling out a general anti-oxidant regulated mechanism of down regulation 
(Ricciarelli et al., 2000). One alternative mechanism is that α-tocopherol inhibited protein 
kinase C (PKC) activity and it is the phosphorylation/dephosphorylation of the CD36 
PPARγ transcription factor that may be involved in the down regulation of CD36. A second 
proposed mechanism was that α-tocopherol could modulate gene expression indirectly via 
inhibiting the activated oxidised form of PPARγ ligands. Evidence of α-tocopherol acting 
by this pathway came from an experiment showing that it reduced the level of PPARγ 
activators 9-Hydroxyoctadecadienoic acid (9-HODE) and 13-HODE by inhibiting their 
enzymatic production (Belkner, Stender, & Kühn, 1998). 
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1.5.4 Other modes of CD36 down regulation 
Transforming growth factor-β1 (TGF-β1) and TGF-β2 have been shown to down- regulate 
CD36. Han et al., (2000) showed that TGF-β1 and TGF-β2 decreased expression of CD36 
in THP-1 cells by a mechanism involving phosphorylation of mitogen activated protein 
(MAP) kinase which in turn initiated phosphorylation of PPARγ leading to a decrease in 
CD36 gene transcription.  
Alongside the transforming growth factors Boyer et al. showed a mechanism for CD36 
down regulation in the form of the cytokine TNF-α which is known to play a major role in 
the development of atherosclerosis (Boyer et al., 2007). Using human monocytes Boyer et 
al. showed that TNF-α inhibited both CD36 membrane expression and mRNA expression 
in a process involving a reduction in PPARγ activation (Boyer et al., 2007). These results 
corresponded well to studies in which a reduction in PPARγ activation by TNF-α was 
reported in human adipocytes and hepatocytes (Sung, She, Xiong, & Tsukamoto, 2004). 
Further evidence for the role that this cytokine plays in CD36 down regulation came from 
a study by Zamora et al. (2012) who showed TNF-α trigged CD36 down regulation in toll 
like receptor 2 (TLR2) and TLR4 ligand lipopolysaccharide (LPS) stimulated human 
peripheral blood mononuclear cells (PMBC). Additional anti-inflammatory cytokines have 
also been suggested to play a role in CD36 down regulation. Rubic et al. using THP-1 cells 
and peripheral monocytes showed that anti-inflammatory cytokine interleukin-10 (IL-10) 
suppressed basal and PPARγ stimulated transcription of CD36 due to reduced PPARγ 
protein expression (Rubic & Lorenz, 2006). However this is contrasted in the study by 
Zamora et al. (2012) who although agreed that IL-10 along with IL-6 were produced during 





Figure 1.5 Protective mechanisms of 7,8-NP 
7,8-NP produced by GTP stimulated macrophages is thought to protect against atherosclerosis by 
scavenging radicals and in so preventing oxLDL and subsequent foam cell formation, along with 
down-regulating CD36, the main scavenger receptor of oxLDL.  
 
1.6 Peroxisome proliferator activated receptor-ɣ 
CD36 transcription is known to be controlled by the heterodimer Peroxisome Proliferator 
Activated Receptor-γ/Retinoid X Receptor (PPARγ/RXR) (S. Han & Sidell, 2002) with 
PPARγ ligands 15-deoxyD12 and 14-prostaglandin J2 increasing CD36 expression (Feng 
et al., 2000). PPARγ is a member of the PPAR subfamily of nuclear hormone receptors 
which act as ligand-activated transcription factors, regulating gene expression by 
interacting with specific DNA sequences upstream of target genes. The PPAR subfamily 
names relates to the ability of the original member PPARα to induce peroxisome 
proliferation in response to a variety of compounds (Lee et al., 1995). Other PPAR 
members do not necessarily share this function, instead acting as major regulators of the 
numerous aspects of lipid metabolism and metabolic control. Using PPARα as a base 
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PPARγ was first identified using homology cloning in Xenopus (Dreyer et al., 1992) and 
subsequently in mice (Zhu, Alvares, Huang, Rao, & Reddy, 1993). Afterwards it was 
discovered to act as the main regulator of adipogenic differentiation (Tontonoz & 
Spiegelman, 2008). 
1.6.1 PPARγ structure and function 
Common to all members of the PPAR subfamily, PPARγ forms an obligate heterodimer 
with RXR in order to carry out its function (Kliewer et al. 1997), with lack of dimerization 
compromising PPARγ’s ability to bind to DNA with high affinity. The C-terminal region 
of PPARγ is required for RXR dimerization and also contains AF2, the major 
transcriptional activation domain, along with forming a ligand-binding pocket (Tontonoz 
2008). The 120 amino acids that make up the N-terminal region exhibits transcriptional 
activity when interacting with a heterologous DNA-binding domain. Contradictory 
evidence using deletion studies have shown that when the N-terminal domain is removed 
PPARγ exhibits increased greater transcriptional activity suggesting that this domain may 
also contribute a level of inhibitory function (Tontonoz, Hu, & Spiegelman, 1994).  
1.6.2 Modulation of PPARγ activity  
PPARγ is a phosphoprotein in which it can be post-translationally modified by the 
attachment of a phosphate group by MAP kinases (Figure 1.6). In contrast to the likes of 
insulin this modification decreases transcriptional activity (Adams, Reginato, Shao, Lazar, 
& Chatterjee, 1997; Hu, Kim, Sarraf, & Spiegelman, 1996). In vitro assays have shown that 
two MAP kinases ERK1/2, and JNK are able to phosphorylate the PPARγ leading to a 
decrease in transcriptional activity, including that of CD36 (Adams et al., 1997; Camp & 
Tafuri, 1997). Phosphorylation mediate by both these MAP kinases has been shown to 
occur at the same site at serine 82 of mouse PPARγ1 (Shao et al., 1998). The substitution 
by alanine here causes the loss of platelet-derived growth factor mediated repression of 
PPARγ activity (Camp & Tafuri, 1997). In humans phosphorylation at the corresponding 
S84 site was shown to inhibit ligand dependent as well and independent trans-activating 
function.  A separate study also showed that mutation at the MAP kinase binding site lead 
to a decrease in ligand binding affinity (Han et al., 2000) which may suggest 
communication between phosphorylation and ligand binding sites, similar to that seen in 
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PPARα. In murine models PPARγ 2 is able to be phosphorylated at serine 112 culminating 
in decreased PPARγ activity (Adams et al., 1997; Hu et al., 1996).  
PPARγ function can also be regulated by ligand binding. Bound ligands induce a 
conformational change which allows for the release of transcriptional inhibitors and the 
recruitment of transcriptional co-activators. One class of ligands involves redox-regulation. 
The oxidised lipid 15-deoxy-Δ12,14-PGJ2 has been shown to act as a ligand (Forman et 
al., 1995), along with 9-(HODE), 13-(HODE) (Lenz et al., 1990) and 15(S)-HETE (Nagy, 
Tontonoz, Alvarez, Chen, & Evans, 1998).  
One pathway of ligand activation involves the STAT1 signalling pathway and 15(S)-
HETE. Activated STAT1 forms a homodimer which when translocated to the nucleus will 
bind consensus DNA γ-activated sites and activate transcription (O'Shea, Gadina, & 
Schreiber, 2002; Ramana, Gil, Schreiber, & Stark, 2002). Interaction of STAT1 with 
PPARγ requires it to become actytelated, but not phosphorylated. Acetylation requires p300 
activation which in turn requires Syk2 and Pyk2 stimulation and XO and NADPH oxidise 
mediated ROS production. Although the exact mechanism of how 15(S)-HETE activates 











Figure 1.6 Regulation mechanics of PPARγ in atherosclerosis 
The regulation mechanics of PPARγ induced down regulation shows a activated MAP Kinase 
cascade within the macrophage resulting in the phosphorylation of PPARγ’s kinase binding site 
subsequently decreasing the transcriptional activity for CD36. Oxidised ligand and STAT1 
activation of PPARγ is also shown. 
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1.7. MAP kinases 
Mitogen-activated protein kinases (MAP kinase) are a highly conserved family of protein 
kinases specific to the amino acids serine, threonine, and tyrosine. MAP kinase signalling 
pathways are involved in a wide variety of cellular functions including proliferation, 
differentiation, motility, stress response, apoptosis, and survival. Classic MAP kinases 
include the extracellular signal-regulated kinase 1 and 2 (Erk1/2), the c-Jun N-terminal 
kinases 1-3 (JNK1-3), the p38 isoforms (p38α, β, γ, and δ) and Erk5. These share number 
of characteristics including similar substrate sites, phosphorylation dependent activation 
and a “three-tiered” pathway structure in which phosphorylation cascades transmit 
movement of the signal from one “tier” to the next. 
A diverse range of extracellular stimuli trigger MAP kinase activation. Such stimuli include 
mitogens, cytokines and growth factors. A stimuli will initially activate one or more MAP 
kinase kinase kinases (MAPKKKs) either by a receptor dependent or independent 
mechanism in the initial “tier”. MAPKKKs can then phosphorylate and activate a 
downstream MAP kinase kinase (MAPKK), the second “tier” which in turn phosphorylates 
and activates MAP kinase. MAP kinase activation can then trigger the phosphorylation and 
activation of MAP kinase-activated protein kinases (MAPKAPKs) which function to 
amplify and mediate the wide range of biological process required. 
1.7.1 ERK cascade 
ERK MAP kinases (otherwise known as the classical MAP kinase) cascades are involved 
in a wide variety of cellular functions including in adhesion, progression, migration, 
survival, differentiation, metabolism, proliferation, and transcription (Roskoski, 2012). 
ERK1/2 is activated by dual phosphorylation on tyrosine and threonine by the MAPKKs 
MEK1 and MEK2 (Cobb, Boulton, & Robbins, 1991). These in turn are activated by the 
MAPKKKs Raf-1, B-af and c-MOS. Termination of ERK1/2 activation is dependent on 
regulatory mechanisms that remove one or both phosphates by tyrosine or serine/threonine 




1.7.2 JNK cascade 
JNK kinase cascades are involved in mediating the cellular apoptotic response to pro-
inflammatory genotoxins along with having a role in the regulation of cell proliferation, 
survival and differentiation (C. Davies & Tournier, 2012). JNK is selectively 
phosphorylated and activated by JNKKs MKK4 and SEK, which in turn are activated by 
the MAPKKKs MEKK1/2 and Tpl-2. 
1.7.3 P38 cascade 
The p38 MAP kinase and its signalling cascades are activated by stress and plays a role in 
immune response, cellular survival and differentiation (Cuadrado & Nebreda, 2010). Four 
p38 MAP kinase isoforms have been identified with the p38α and p38β isoforms being 
ubiquitously expressed (Ono & Han, 2000). The p38 pathway is activated by the MAPKKs 
MKK3, JNKK and MEK6 and MAPKKKs Rac-1, Cdc42 and PAK. In most inflammatory 
cells p38α is the predominately activated isoform with extracellular stimuli coming from a 
variety of cytokines and a number of pathogens that activate though different toll-like 
receptors. Several growth factors as well as environmental factors such as heat shock, 
osmotic regulation, UV light, hypoxic stress and oxygen radicals and also capable of 
inducing activation. 
1.7.4 MAP kinases & atherosclerosis 
Reactive oxygen species such as superoxide and hydrogen peroxide have been shown to be 
produced in vascular smooth muscle cells (VSMC), endothelial cells and cardiomyocytes 
(Abe & Berk, 1998; Griendling, Sorescu, & Ushio-Fukai, 2000; Yoshizumi, Tsuchiya, & 
Tamaki, 2001). There is evidence that MAP kinases play a role in vascular remodelling 
alongside these reactive oxygen species.  MAP kinases have been shown to be impacted by 
oxidative stress with hydrogen peroxide significantly stimulating ERK1/2, JNK and p38 is 
rat aortic smooth muscle cells (Yoshizumi, Abe, Haendeler, Huang, & Berk, 2000) 
Angiotensin II and endotheilan I also activate MAP kinases in VSMC and have been 
suggested to be a cause of vascular remodelling (Ishida, Ishida, Thomas, & Berk, 1998) 





1.8 Objective of research 
OxLDL uptake by macrophage CD36 leading to foam cell formation is one process at the 
core of atherosclerotic plaque development. Mechanisms that are able to decrease levels of 
CD36 are of increasing interest in order to slow the progression of atherosclerosis. One 
potential mechanism for CD36 down regulation involves the human macrophage derived 
anti-oxidant 7,8-NP which has been shown to decrease basal CD36 levels in human 
monocyte derived macrophages (HMDM). In this study it is hypothesised the 7,8-NP is 
exerting its effect via interaction with the PPARγ transcription factor. Specifically it is 
thought that 7,8-NP is activating a MAP Kinase cascade with the end result being the 
phosphorylation of the PPARγ MAP kinase binding site and a subsequent decrease in CD36 
transcription.  
The first objective of this research will be to confirm that the 7,8-NP induced down 
regulation seen in HMDMs occurs in the U937 monocyte like cell line. This will include 
looking at the effects of time and concentration on CD36 levels, and also whether recovery 
after down regulation is possible. 7,8-NP induced down regulation will be explored mainly 
using western blotting, with cell lysate after experimental treatment being immunoblotted 
for the CD36 antibody. The effectiveness of flow-cytometry will additionally be explored 
using CD36 antibody binding to the cell surface of whole cells. The next part of this thesis 
will confirm that CD36 transcription is under the control of PPARγ in the U937 cell line 
using a selective PPARγ inhibitor in order to confirm our choice of target. It will also be 
investigated whether 7,8-NP alternatively has its effect via enhancing CD36 degradation 
using the protein synthesis inhibitor cycloheximide. The research will then explore the 
effects of MAP kinases on 7,8-NP induced CD36 down regulation. This will be achieved 
using selective MAP kinase inhibitors including those to ERK1/2, JNK and p38. The effect 
of NF-κB inhibition will also be explored.  
This research will help determined the mechanism via which 7,8-NP induces CD36 down 
regulation and help to improve our understanding on the role the 7,8-NP plays in the 





2. MATERIALS & METHODS 
 
2.1 Reagents, media and buffers 
All reagents were of analytical grade. All solutions were prepared with deionized water 
purified with a Milli-Q ultrafiltration system (Millipore, Massachusetts, USA). This water 
is referred to as nano-pure water in this thesis. 
2.1.1 Reagents 
β-Mercaptoethanol      Sigma Chemical Co., Missouri, USA 
4-Morpholine-propanesulfonic acid (MOPS)   Sigma Chemical Co., Missouri, USA 
7,8-Dihydroneopterin (7,8-NP)     Schircks Laboratory, Switzerland 
Acetic acid (glacial)      BDH Lab Supplies, Poole, England 
Anchor non-fat milk powder  Fonterra Ltd, New Zealand 
BAY 11-7082 (NF-κB Inhibitor)    Sigma-Aldrich Co. LLC, New Zealand 
Bicinchoninic acid (BCA) protein determination kit  Pierce Biotechnolgy Inc., Illionois, USA 
Bovine serum albumin (BSA)     Sigma-Aldrich Co. LLC, New Zealand 
Bromophenol blue      Sigma-Aldrich Co. LLC, New Zealand 
cOmplete™, Mini Protease Inhibitor Cocktail   Sigma-Aldrich Co. LLC, New Zealand 
Coumassie blue      Bio-Rad Laboratories, California, USA 
Dimethyl sufloxide (DMSO)     BDH Lab Supplies Ltd, Poole, England 
Ethanol       BDH Lab Supplies Ltd, Poole, England 
Ethylene-diamine-tetra-acetic acid (EDTA)  Sigma-Aldrich Co. LLC, New Zealand 
Glycerol       Sigma-Aldrich Co. LLC, New Zealand 
GW9662 (PPAR-ɣ inhibitor)     Sigma-Aldrich Co. LLC, New Zealand 
Hydrochloric acid (HCl)     Merck, Germnay 
Methanol       Merck, Fischer Scientific, Belgium 
Molecular weight marker     Bio-Rad Laboratories, California, USA 
Neopterin      Schircks Laboratory, Switzerland 
NuPAGE 4-12% Bis-tris Gels, 1.0mm x10 well   Invitrogen, California, USA 
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NuPAGE 4-12% Bis-tris Gels, 1.5mm x15 well   Invitrogen, California, USA 
PD98059 (MEK Inhibitor)     Sigma-Aldrich Co. LLC, New Zealand 
Phorbol 12-myristate 13-acetate (PMA)    Sigma Chemical Co., Missouri, USA 
Ponceau S       Sigma Chemical Co., Missouri, USA 
SB202190 (p38 inhibitor)     Sigma-Aldrich Co. LLC, New Zealand 
Sodium bicarbonate (NaHCO3)    Sigma-Aldrich Co. LLC, New Zealand 
Sodium chloride (NaCl)     BDH Lab Supplies Ltd, Poole, England 
Sodium dodecyl sulphate (SDS)    Sigma-Aldrich Co. LLC, New Zealand 
Sodium hydroxide (NaOH)     BDH Lab Supplies Ltd, Poole, England 
SP600125 (JNK Inhibitor)     Sigma-Aldrich Co. LLC, New Zealand 
Supersignal West Dura Chemiluminescence   Pierce Biotechnolgy Inc., Illionois, USA 
Thimerosal       Sigma Chemical Co., Missouri, USA 
Tris(hydroxymethyl)aminomethane    Sigma-Aldrich Co. LLC, New Zealand 
Triton X100      Sigma-Aldrich Co. LLC, New Zealand 
Trypan blue solution (0.4%)     Sigma-Aldrich Co. LLC, New Zealand 
Tween 20®       Sigma-Aldrich Co. LLC, New Zealand 
2.1.2 Media 
Penicillin/Streptomycin solution:  Invitrogen, Life Technologies, New Zealand 
1000 U of Penicillin G &                                                                                                 
1000 µg of Streptomycin/mL  
RPMI 1640 media, with phenol red   Sigma-Aldrich Co. LLC, New Zealand 
RPMI 1640 media, without phenol red  Sigma-Aldrich Co. LLC, New Zealand 
2.1.3 General solutions and buffers 
A. Roswell Park Memorial Institute (RPMI)-1640 media (with or without    
phenol red) 
Powered RPMI-1640 (Sigma-Aldrich Co. LLC, New Zealand) was prepared in accordance 
to the manufacturer’s instructions. RPMI-1640 was dissolved in nano-pure water before 
addition of sodium bicarbonate (NaHCO3) and adjustment of pH to 7.4 by the addition of 
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11.4M hydrochloric acid (HCl). The RPMI-1640 medium was next sterilized by filtration 
through a 0.22 µM Millex® filter (Sartorius AG, Goettingen, Germany) and a peristaltic 
pump (CP-600, Life Technologies, Maryland, USA) into sterile 500 mL bottles previously 
washed with nitric acid and autoclaved. Prepared media was stored at 4oC. 
Premade sterilized RPMI-1640 was also used (HycloneTM, GE Healthcare Life Sciences, 
Utah, USA) pre-supplemented with sodium bicarbonate, pH 7.4 
B. Phosphate buffered saline (PBS) 
PBS buffer consisted of 150mM sodium chloride (NaCl) and 10mM sodium dihydrogen 
orthophosphate (NaH2PO4) at pH 7.4. The solution was prepared by mixing 50 mL of 3M 
NaCl, 40 mL of 250mM NaH2PO4, pH 7.4 and 910 mL of nano-pure water. PBS required 
for sterile cell culture experiments was sterilized by autoclaving (15 minutes, 121oC, 15 
PSI). 
C. 7,8-dihydroneopterin solution 
A 1mM 7,8-Dihydroneopterin (7,8-NP) (Schircks Laboratories, Switzerland) stock 
solution was prepared in RPMI 1640 media, in a 15 mL screw top centrifuge tube (Greiner, 
Greiner Bio-one, Neuburg, Germany). The solution was sonicated for 10 minutes or until 
dissolved before being sterilized by passage through a 0.22µM PES syringe filter 
(Membrane Solution, USA). The 7,8-NP solution was kept on ice at all times and used 
immediately after preparation. 
D. D-neopterin solution 
Neopterin stock solution (1mM) was prepared by dissolving D-neopterin powder (Schircks 
Laboratories, Switzerland) in RPMI-1640 via sonication in a 15 mL screw top centrifuge 
tube (Greiner, Greiner Bio-one, Neuburg, Germany). The solution was sonicated until 
dissolved before being sterilized by passage through a 0.22µM PES syringe filter 
(Membrane Solution, USA). The neopterin solution was kept on ice at all times and used 
immediately after preparation. 
E. Triton lysis solution 
Lysis solution consisted of 0.5% Triton-X100 (diluted from 1% stock solution in nano-pure 
water). Protease inhibitor (ProteaseMini, Roche Diagnostics) prepared and frozen to the 
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manufacturers recommendations (ProteaseMini, Roche Diagnostics), was defrosted and 
added to the lysis solution on the day of use.  
F. MOPS buffer for SDS-PAGE 
 A 10x stock solution of MOPS was made with 500mM MOPS, 500mM Tris base, 1% SDS 
(w/v), and 10mM EDTA in water with pH adjusted to 7.7 (adjusted with concentrated HCl). 
Stock solution was diluted with nano-pure water to 1x concentration before use. 
G. Transfer buffer for western blotting 
Transfer buffer consisted of 25mM Tris, 200mM glycine and 20% methanol (v/v) in water 
and was stored at 4oC. Transfer buffer was able to be reused once.  
H. Tris-buffered saline (TBS) 
TBS used for nitrocellulose membrane washing, consisted of 40mM Tris-HCl, 150mM 
NaCl, 0.05% Tween20 (w/v) and 0.01% thimerosal (w/v) dissolved in nano-pure water. 
Final pH was adjusted to 7.5 using concentrated HCl.  
I. TBSM 
The membrane blocking solution (TBS-milk, TBSM) consisted of 5% (w/v) of nonfat milk 
powder (Anchor, New Zealand) dissolved in TBS. It was stored at 4◦C for up to one week.  
J. Cracker buffer for SDS-PAGE 
 To make the cracker buffer, 125mM Tris-HCl, pH 6.8 (adjusted with concentrated HCl), 
1% SDS (w/v), 20% glycerol (w/v) and 0.1% bromophenol blue (w/v) were mixed in nano-
pure water. Immediately prior to use, 2% (v/v) of β–mercaptoethanol and 0.5mM EDTA 
was added to the amount required of the above solution.  
K. Restore stripping buffer 
Restore stripping buffer solution used to remove antibodies from the nitrocellulose 
membrane in preparation for reprobing consisted of 2 % SDS, 50mM Tris pH 6.8 , and 
100µM β–mercaptoethanol and made up to volume in nano-pure water. 
L. Ponceau S stain 
 Ponceau S stain consisted of 0.01% Ponceau S (w/v) in 5% acetic acid (v/v).  
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M. Propidium iodide solution 
A 1 mg/mL stock solution of propidium iodide dye (Sigma-Aldrich Co. LLC, New 
Zealand) was prepared in nano-pure water and was kept in a sterilized schott bottle, 
wrapped in tin foil at 4oC 
N. Phorbol 12-myristate 12-acetate (PMA) 
A 5mM PMA stock solution was prepared by dissolving PMA powder in DMSO. 20 µL 
aliquots were pipetted into 1.7 mL centrifuge tubes and stored at -20oC  
2.2 Methods 
2.2.1 Cell culture based experiments 
2.2.1.1 Aseptic technique 
All work involving cell culture was performed under aseptic conditions using a Class II 
biological safety cabinet (Clyde-Apex BH 200). All cell culture equipment used was sterile-
brought plastic ware (Falcon, Terumo, Unomedical, Greiner Bio-one) or had been sterilized 
by autoclaving (15 miniutes, 121oC, 15 PSI). All media/solutions added to cells was 
sterilized by autoclaving or by filtration using a 0.22 µm filter (Membrane Solutions, USA). 
All equipment was sprayed with 70% ethanol (diluted from stock solution in distilled water) 
before use in the Class II safety cabinet. Cells were kept incubated in a humidified 
atmosphere at 37°C containing 95% air w/ 5% CO2 (Sunnyo Electric Cp. LTD, Japan). 
2.2.1.2 Standard RPMI-1640 media for U937 cell culture 
RPMI-1640 with phenol red enriched with 100 U/mL penicillin G, 100 µg/mL 
streptomycin and 5% (v/v) foetal bovine serum (FBS) was used as standard in U937 cell 
culture maintenance.  
2.2.1.3 Preparation and culture of the U937 cell line 
The U937 cell line is a type of immortal cell line derived from the malignant cells of a 
pleural effusion from a patient with diffuse histiocytic lymphoma, and are one of the few 
human cell lines expressing monocyte like characteristics exhibited by cells of histiocytic 
origin. The U937 cells used in this work were from a line gifted by the Haematology 
Resesearch Laboratory of the Christchurch School of Medicine, University of Otago.  
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Prior to revival stock U937 cells were stored in liquid nitrogen using 1 mL storage vials 
containing 10x106 cells/mL in dimethyl sulfoxide (DMSO) freezing medium. To prepare 
stock U937 for use one vial was defrosted in a 37oC water bath until almost fully thawed. 
This suspension was next poured into 20 mL of RPMI-1640 and centrifuged at 500g for 5 
minutes in order to separate the DMSO from the cells. The cell pellet was re-suspended in 
10 mL of RPMI-1640 before being cultured in 25 cm3 tissue culture flasks (Flacon, BD, 
USA) until the cells were deemed fully recovered from their storage state and transferred 
into a standard 75 cm3 tissue culture flask (Greiner Bio-one, Germany). 
Cells were deemed suitable for experimental work once they had reached an approximate 
density of ~1x106 cells/mL and division rate had normalized to a doubling time of 92-96 
hours. These cells showed a spherical morphology with small grain like protrusions on the 
membrane from cytoplasmic organelles, and with little clustering or blebbing. Subsequent 
cell density was maintained between 0.3-1.5x106 cells/mL by passaging every 2-3 days. 
2.2.1.4 Cell culture experimental conditions and procedures 
Experiments with the U937 cell line were performed using either 12 or 24-well suspension 
culture plates (Cellstar ®, Greiner Bio-one). The total volume used during experimental 
work was 1 mL per well. Cells were counted using a haemocytometer in conjunction with 
a light microscope after dilution with trypan blue (ratio of 1:1). The required amount of 
cells was centrifuged at 500 g for 5 minutes at room temperature then re-suspended in the 
required experimental medium pre-heated to 37oC using a water bath. The cells were then 
aliquoted into the plate wells to a final concentration of 0.5x106 cells/mL. 
2.2.2 Cell viability assays 
2.2.2.1 Propidium iodide cell viability assay 
U937 cell viability was measured after experimental treatment via the use of propidium 
iodide (PI) staining and flow cytometery (BD AccuriTM C6 flow cytometer, BD 
Biosciences, California, USA). PI is able to intercalate between DNA bases when the cell 
membrane becomes compromised during cell death. Intercalation can be measured via 
fluorescence at an excitation wavelength of 535 nM and emission wavelength of 617 nM. 
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Combined with the use of a flow cytometer PI can be used to examine cell viability along 
with identifying necrotic, apoptotic and healthy cells. 
After experimental treatment 250 µL of cell suspension was incubated with 4 µL of 
1mg/mL PI and mixed via inversion. Incubation was allowed to occur in the dark for 10 
minutes. Viability was measured using a set volume (30 µL) analyzed on the flow 
cytometer using forward scatter (FSC) and the fluorescence filter FL-3 (FL-3). Cellular 
debris were identified and excluded from analysis and the cellular viability ratio (PI+ve:PI-
ve) was compared to control samples. 
2.2.2.2 Trypan blue viability test 
The trypan blue viability tests is a dye exclusion test which is used to determine the number 
of viable cells present in a cell suspension. Live cells contain intact cell membranes that 
exclude the Trypan Blue dye, whereas non-viable cells have compromised cellular 
membranes that allow for the dye to enter the cellular cytoplasm staining it blue. 
After experimental treatment the cellular suspension was diluted in a 1:1 ratio with 0.4% 
Trypan Blue solution and incubated for two minutes. The suspension was then transferred 
to a hemocytometer and the number of viable and non-viable cells counted. Viable cells 
were identified as having a white or clear cytoplasm, while non-viable cells were identified 
as having a blue cytoplasm. The ratio of viable:non-viable cells was then calculated and 
cellular viability determined. 
2.2.3 Determination of protein concentration 
Protein concentration of cell lysate was quantified using the bicinchoninic acid (BCA) 
protein determination kit assay (PierceTM, Rockford, USA) in which the reduction of Cu2+ 
to Cu+ by protein in an alkaline medium can be measured via a BCA reagent. The reaction 
product of this assay exhibits strong absorbance at 562nM with increasing protein 
concentration in the range of 25–250µg/mL. 
Fresh working reagent was prepared prior to each use by combining Reagent A (NaCO3, 
NaHCO3, BCA and sodium tartrate in 0.1M sodium hydroxide) and reagent B (4% 
CuS04.5H2O) at a ratio of 50:1 (5 mL Reagent A to 100 µL Reagent B). The assay was run 
by mixing 50 µL of cell lysate (diluted in nano-pure water as required) with 1 mL of 
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working reagent prior to a 30 minute incubation on a shaking heating block at 60o C to start 
the reaction. When complete the reaction was stopped by placing the samples on ice until 
cool and the absorbance read at 562 nM against a water blank. Protein concentration was 
determined using a standard curve by measuring the absorbance of known concentrations 
of BSA (0-250 µg/mL) under the same conditions. 
2.2.4 SDS-PAGE  
2.2.4.1 Cell lysate preparation.  
U937 samples for western blot were prepared in the following manner. All medium within 
the wells were pippeted up and down to dislodge the cells into suspension before transfer 
into 1.7 mL centrifuge tubes. Cells were centrifuged for 15,000g at 0◦C for 5 minutes in 
order to pellet cells. The supernatant was discarded and cells re-suspended in sterilized ice 
cold PBS before being centrifuged at 15,000 g at 0oC for 5 minutes in order to wash the 
cells. The supernatant was discarded and 150 µL of ice-cold lysis buffer (containing 
protease inhibitor) was added to each centrifuge tube and left on ice for 25 minutes in order 
to ensure lysation. Cell lysate was stored at -80oC degrees until analyzed. 
2.2.4.2 SDS-polyacrylamide gel electrophoresis  
The required amount of sample as determined by protein concentration (generally 50 µg at 
volumes ~30-50 µL) was aliquoted into 1.7 mL centrifuge tubes. 400 µL of ice-cold acetone 
was added to each tube and centrifuged for 15,000 at 0oC for 10 minutes to pellet the cells. 
The supernatant was discarded and the tubes were left in a fume hood for any residual 
acetone to evaporate. The pellet was re-suspended in fresh cracker buffer containing 2% β-
mercaptoethanol to a final protein concentration of 2µg protein per µL. The samples were 
then heated in a heating block at 90oC for 2 minutes to denature the protein. The samples 
were then centrifuged for 5 minutes at 20,000g in preparation for loading. 5 µL of pre-
stained molecular weight marker mix (Fermentas International Inc, Ontario, Canada) and 
25 µL/well of sample were loaded into the gel wells. The gel (4-12% Bis-Tris Gel, 
Invitrogen, California, USA) was run at 100V at 300mA in 1x MOPS buffer until the dye 
had run past the wells, and 200V at 300mA thereafter until the dye had reached the bottom 
of the gel. 
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2.2.5 Western blot analysis 
2.2.5.1 Protein transfer 
Proteins separated on the SDS-PAGE gel were transferred onto a nitrocellulose membrane 
using either wet or semi-dry transfer protocols. For the wet method transfer occurred over 
800 minutes at 70V in a water cooled tank transfer electrophoresis unit (TE22, Hoefer, 
USA) containing the transfer buffer. For the semi-dry method transfer occurred at 1.3A, 
25V for 10 minutes using the Trans-Blot® Turbo™ Transfer System (Bio-Rad 
Laboratories, California, USA) following the manufactures instructions. 
The following steps were all undertaken on a rocking platform mixer (Ratex Instruments, 
Australia). Once transfer had been completed the nitrocellulose membrane was rinsed with 
nano-pure water and incubated with 0.01% Ponceau S stain for 1 minute to check transfer 
efficiency. Efficient transfer showed distinct pink columns forming at the location of each 
well. The membrane was then blocked using 5% TBSM for 1.5-2 hours with the TBSM 
being replaced every 30 minutes. During this time the Ponceau S stain completely 
disappeared.  
2.2.5.2 CD36 immunostaining 
Following blocking the nitrocellulose membrane was incubated with rabbit polyclonal 
affinity purified antibody raised against human CD36 (NB400-145, Novus Biologicals Inc., 
USA) for 1.5 hours diluted to 1:1,000-2000 in 1% TBSM. The nitrocellulose membrane 
was then washed 5 times for 5 minutes in TBS before undergoing incubation for 1 hour 
with the secondary antibody; goat polyclonal anti-rabbit IgG, conjugated to hydrogen 
peroxidase (HRP) (NB730-H, Novus Biologicals Inc., USA) diluted to 1:2,000. Incubation 
was followed by 5 lots of 5 minute washes in TBS before being briefly rinsed with nano-
water prior to visualization.  
2.2.5.3 Visualization 
Visualization of the antibody staining was achieved via chemiluminescence signaling 
corresponding to the location of the HRP-conjugated secondary antibody. The signal was 
produced by incubating the nitrocellulose membrane with Supersignal West Dura 
Chemiluminescence (TerumoScientific, USA) substrates A & B, mixed at a ratio of 1:1. 
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Images containing the signal were obtained at high resolution, without filter or light, using 
the time-lapse auto-exposure setting on a Syngene Chemigenius-2 bioimaging system 
(USA). The images were then analyzed for band intensity using GeneSnap (Syngene, USA) 
and ImageJ64 1.42q. 
2.2.5.4 Nitrocellulose membrane stripping and β-Actin probing 
Re-probing of the nitrocellulose membrane for β-actin was always subsequent to 
visualization of CD36 during which time the nitrocellulose membrane was kept in TBS at 
4◦C. Prior to re-probing for β-actin the nitrocellulose membrane was stripped of all previous 
antibodies via incubation with stripping buffer (2% SDS, 50mM Tris, 100µM β–MEtOH, 
pH 6.8, heated to 50◦C on a water bath) for 20 minutes, followed by 5 lots of 5 minute 
washes in TBS. Reprobing for β-actin was done directly after stripping without blocking.  
Once stripping was completed the nitrocellulose membrane was incubated with mouse 
monoclonal antibody raised against β-actin (A5316, Sigma-Aldrich Chemical Co., USA) 
for 1.5 hours diluted to 1:7,500 in 1% TBSM. The nitrocellulose membrane was then 
washed 5 times for 5 minutes in TBS before undergoing incubation for 1 hour with the 
secondary antibody; anti-mouse IgG Peroxidase-linked NA931 (GE Healthcare, UK) 
diluted to 1:7,500 in 2% TBSM. Incubation was followed by 5 lots of 10 minute washes in 
TBS before being briefly rinsed with nano-pure water prior to visualization.  
2.2.6 Flow cytometry determination of U937 CD36 cell surface 
expression 
Flow cytometry is a powerful technique that is able to analyze the fluorescence of 
individual cells passing through a laser light source. The fluidic systems within the flow 
cytometer uses hydrodynamic focusing to arrange the particles in a sample into a straight 
stream that passes through the light source. The flow cytometer then collects light scattering 
and fluorescent emission information about the particle to reveal information about its 
properties. The flow cytometer contains two separate detectors, the Forward Scatter 
Channel (FSC) which is offset 20 degrees from the beam axis, and the Side Scatter Channel 
which is offset 90 degrees. The patterns generated from these two detectors are unique for 
35 
 
every particle and provides information of particle size, granular content, while also 
allowing identification of live cells and cellular debris.   
Cells were extracted from experimental wells and centrifuged in a pre-cooled centrifuge 
tube (4oC) for 5 minutes at 2000 rpm. The supernatant was then discarded and the cells re-
suspended in 245 µL PBS + 0.5% BSA. 5 µL of Purified Mouse Anti-Human CD36 
primary antibody (BD Biosciences) was added and incubated on ice for 20 minutes (final 
concentration: 10µg/mL mouse anti-human CD36). The cells were then centrifuged for 5 
minutes at 2000 rpm before being re-suspended in 190 µL PBS +0.5% BSA and 10 µL of 
secondary antibody Polyclonal Goat Anti-Mouse Immunoglobulins/RPE Goat F(ab’)2 
added. Incubation on ice was allowed to occur for 20 minutes before the cells where 
centrifuged 5 minutes at 2000 rpm and brought back up in 1mL PBS +0.5% BSA. 10,000 
events were then analysed on the FL2 filter using the BD Biosciences Accuri C6 Flow 
Cytometer. A primary antibody control (IgMk) was used also to ensure that all labeling 
detected was purely due to CD36 antibody binding. 
2.2.7 Statistical analysis 
The results presented in this thesis were graphed and statistically analyzed by GraphPad 
Prisim version 6.01 for Windows (GraphPad Software, San Diego, California, USA). 
Significance was confirmed via either, one-way or two-way analysis of variance 
(ANOVA). Significance levels are indicated as: (*) p≤  0.05, (**) p≤ 0.01 and (***) p≤ 
0.001. Unless stated otherwise results presented within this thesis are shown in triplicate 
from at least three representative experiments. The graphs are presented as the mean and 











3.1 Characterising the expression of CD36 
3.1.1 The U937 cell line produces detectable basal levels of CD36 
Prior research exploring the down regulation of CD36 has focused mostly on the down 
regulation of this scavenger receptor after an up regulation event (Draude & Lorenz, 2000; 
Han et al., 2000). In contrast this research instead focuses on the down regulation of CD36 
from the basal levels that naturally occur in the U937 cell line. Before research could 
commence it first had to be determined at what levels basal CD36 could be detected using 
western blotting protocols. To determine this U937 cells were incubated in RPMI-1640 
with 5% FBS for 24 hours. Due to basal CD36 levels being the only ones of interest no 
additional treatments were added. Cell lysate was then immunoblotted for CD36 with β-
actin used as a loading control. It was found that a strong CD36 band could be detected at 
the ~100 kDa mark, with a weaker band present at ~88 kDa (Figure 3.1.1). Different bands 
represent the different glycosylation isoforms and maturity levels of the CD36 protein. The 
88 kDa band is reported to be incompletely glycosylated CD36 located in the Golgi 
apparatus, whereas the fully glycosylated 100 kDA band is mature CD36 residing on the 
plasma membrane (Alessio et al., 1996). The strength of the bands observed was considered 
to be suitable for detecting changes in basal CD36 levels upon treatment. It was decided 
that the main focus of this research would be on the 100 kDa isoform due to the strength of 
the band, and that cell surface CD36 is likely responsible for oxLDL binding leading to 







Figure 3.1.1 The U937 cell line produces detectable basal levels of CD36  
U937 cells (0.5x106 cells/mL) were incubated at 37oC for 24 hours in RPMI-1640 with phenol red. 
Cell lysate was assessed for CD36 protein expression via western blot. Quantitative densitometry 
of western blots shows a strong band at ~100 kDa and a weaker band at ~88 kDa.  
3.1.2 Triton X-100 as a lysing agent 
Before further research could take place, appropriate experiments had to be under taken in 
order to determine an appropriate lysing agent for efficient use with the U937 cell line. 
Previous research using human monocyte derived macrophages (HMDM) in the Free 
Radical Biochemistry (FRB) lab group used a HEPES and NaCl based lysing agent. Initial 
experiments showed that this failed to efficiently lyse U937 cells. To overcome this Triton 
X-100 was considered for use. Triton X-100 is a nonionic surfactant detergent successfully 
used previously in working with the U937 cell line. In order to re-examine its use here 
U937 cells were incubated with increasing concentrations of Triton X-100 of between 0 
and 1.0% for 10 minutes at 37oC. Cell viability and the extent of lysation was determined 
via a light microscope in order to determine the appropriate amount of Triton X-100 
required for complete lysation. Cell images of the Triton X-100 treatments showed that 
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Figure 3.1.2 0.5% TritonX-100 effectively lysis cells 
Images of U937 cells (0.5x106 cells/mL) after incubation with 0–1% Triton X-100 for 10 minutes 
at 37oC. Cells were viewed in tissue culture plates through an inverted microscope (20x 
magnification). The images were taken using a LEICA DMIL microscope with a LEICIA DFC290 















3.1.3 Effect of PMA of U937 expression 
After confirmation that the U937 cell line produced detectable basal levels of CD36 it was 
of interest to further characterise CD36 expression. One aim was to see whether expression 
could be increased and if so to what extent. CD36 expression is known to increase as 
monocytes differentiate into macrophages (Chanput, Peters, & Wichers, 2015). Phorbol-
12-myristate-13-acetate (PMA) is commonly used as a stimuli in the differentiation process 
and was considered an appropriate choice to use here. In order to examine the effect of this 
differentiation agent on CD36 levels U937 cells were incubated in RPMI-1640 with 5% 
FBS and 25nM PMA over a 24 hour time course. After incubation with PMA cell lysate 
was immunoblotted for CD36 with β-actin used as a loading control.  
Results showed that at the 6 hour time point there appeared to be an increase in CD36 
expression to 129.66% of control (Figure 3.1.3). This increase however was non-
significant and had dropped down to 87.93% of control by the 12 hour time point. CD36 
expression then held relatively steady till time course completion at 24 hours at which it 
was found to be present at 92.62% of control. Overall the results showed that at 25nM PMA 
































Figure 3.1.3 PMA has a limited effect on U937 expression 
U937 cells (0.5x106 cells/mL) were treated with 25nM of PMA and incubated at 37oC over a 24 
hour time course in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of duplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (**) p ≤ 0.001. B) Quantitative densitometry of western blots shows PMA having a 
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3.2 Characterization of CD36 down regulation via 7,8-NP 
3.2.1 7,8-NP reduces the expression of the CD36 scavenger receptor in 
the U937 cell Line 
Previous research has shown that the macrophage derived antioxidant 7,8-dihydroneopterin 
(7,8-NP) caused a decreased in CD36 expression at concentrations up to 250µM in HMDM 
cells (Gieseg, Amit, Yang, Shchepetkina, & Katouah, 2010). While the U937 cell line is 
considered to be a good model for research into atherosclerosis, 7,8-NP induced down 
regulation needed to be confirmed here. To achieve this U937 cells were incubated for 24 
hours with 7,8-NP concentrations ranging from 0-150µM. Cell lysate was then 
immunoblotted for the CD36 protein with β-actin used as a loading control. Down 
regulation was observed beginning at 50µM 78-NP with CD36 expression found to be 
54.77% of control (Figure 3.2.1). Expression then decreased further at both 100µM and 
150µM concentrations (44.43% and 42.73% of control respectively). Significance was 
observed at all three data points, with the highest level of significance occurring at 150µM. 
No significant changes were observed between the different concentrations. The strength 
of this down regulation showed that the effect of 7,8-NP on CD36 in the U937 cell line was 
more pronounced compared to that seen with HMDMs, and that 150µM 7,8-NP was the 

























Figure 3.2.1 7,8-NP reduces the expression of the CD36 scavenger receptor in the 
U937 cell line 
U937 cells (0.5x106 cells/mL) were treated with 0-150µM 7,8-NP and incubated at 37oC over a 24 
hour time course in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of triplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots shows 7,8-NP reduces 
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3.2.2 7,8-NP induced down regulation occurs in both adherent and 
suspension well plates 
Two common cell culture plates used in experimental work are adherent and suspension 
plates. In adherent plates cells will interact closely with the plate, forming an adherent layer 
on the well surface, whereas in suspension plates cells are suspended within the media 
minimising well interaction. It is possible that the type of cell culture plate used may have 
an effect on the morphology and differentiation of U937 cells, and subsequently production 
of the heavily glycosylated 100 kDa CD36 band. This is more likely to occur when adherent 
plates are used due to closer interaction between the cells and the plate, which may be 
recognised as a foreign body and trigger the differentiation process. In order to rule out any 
effect due to the type of plate used on CD36 levels, and the subsequent effects of 7,8-NP, 
both adherent and suspension plates were examined for use in CD36 down regulation 
experiments. U937 cells were incubated with increasing concentrations of 7,8-NP ranging 
from 0-150µM for 24 hours in both adherent and suspension plates. Subsequently the cells 
were washed and lysed. Cell lysate was immunoblotted for CD36 with β-actin used as a 
loading control.  
It was found that CD36 could be detected at strong basal levels when using adherent and 
suspension plates, and that a concentration related decrease could be observed with 7,8-NP 
in both cases (Figure 3.2.2). These results show that any U937 interaction with the type of 
plate used has no or a very limited effect on basal CD36 levels and 7,8-NP induced down 
regulation. As such all further experimentation looking at this effect will take place using 
suspension well plates owing to lesser cell-plate interaction and easier use in extracting 














Figure 3.2.2 7,8-NP down regulation can be observed using both adherent and 
suspension plates 
U937 cells (0.5x106 cells/mL) were treated with increasing concentrations of 7,8-NP (0-150µM) 
and incubated at 37oC for 24 hours in RPMI-1640 with phenol red using both adherent and 
suspension well plates. Cell lysate was assessed for CD36 protein expression via western blot. 
Figure shows the quantitative densitometry of western blots and that increasing 7,8-NP 
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3.2.3 7,8-NP down regulation can be observed using both wet and semi-
dry protein transfer protocols 
Western blotting involves the transfer of proteins after polyacrylamide gel electrophoresis 
over to a membrane suitable for antibody probing such as nitrocellulose. Two commonly 
used transfer techniques (wet and semi-dry) were explored for their suitability in 
experimental work looking at the 7,8-NP induced down regulation of CD36. The wet 
transfer technique system uses a larger volume of transfer buffer and is run over a longer 
time period, whereas the semi-dry transfer system uses less buffer and is run over a shorter 
time. The wet transfer system is usually considered to be better suited for larger molecular 
weight proteins, whilst the semi-dry method is thought to be more ideal for smaller proteins. 
To explore any differences in their suitability for this work U937 cells were incubated with 
increasing concentrations of 7,8-NP ranging from 0-150µM with protein transfer occurring 
using either a wet or semi-dry protocol. It was found that both systems were able to detect 
7,8-NP induced down regulation of CD36 to a similar extent as confirmed via antibody 
probing (Figure 3.2.3). Both systems also transferred similar amounts of protein from the 
SDS page gel onto the nitrocellulose membrane as detected via both ponceau staining of 
the nitrocellulose membranes after transfer, along with coumassise blue staining of the SDS 
gel itself (results not shown). However the semi-dry method was found to produce a more 
reliable transfer with almost no air bubbles forming during the transfer process compared 
to the wet transfer method. Overheating of the nitrocellulose membranes was also cut back 
when the semi-dry method was used. Due to these factors the semi-dry system was the 





















Figure 3.3.3 7,8-NP down regulation can be observed using both wet and semi-dry 
transfer protocols 
U937 cells (0.5x106 cells/mL) were treated with increasing concentrations of 7,8-NP (0-150µM) 
and incubated at 37oC for 24 hours in RPMI-1640 with phenol red using both wet and semi-dry 
transfer methods. Cell lysate was assessed for CD36 protein expression via western blot. Figure 
shows quantitative densitometry of western blots and that increasing 7,8-NP concentration reduces 


















7,8-NP (µM)             0          50         100        150        
47 
 
3.2.4 Time course of 7,8-NP induced CD36 down regulation 
Once CD36 down regulation was confirmed in the U937 cell line a time-course was 
performed in order to investigate the speed at which 7,8-NP has its effect. To achieve this 
U937 cells were incubated with 150µM 7,8-NP over a 24 hour time course. During 
incubation the cells were extracted from the wells at 0, 6, 12 and 24 hours and lysed in the 
presence of protease inhibitor. Cell lysate was kept at -80oC until analysis. Once the time 
course was complete the cell lysate was then immunoblotted for the CD36 protein with β-
actin used as a loading control.  
Down regulation was observed beginning at 6 hours with CD36 expression found to be at 
55.12% of control (Figure 3.2.2). CD36 expression then continued to decrease at both 12 
and 24 hour time points (43.56% and 29.16% of control respectively).  Change compared 
to control was significant at all time points, being the most significant at the 24 hour time 
point. No significant changes were observed between the different time points. The results 
suggest that CD36 down regulation occurs rapidly within the first six hours of incubation 






















Figure 3.2.4 7,8-NP down regulates CD36 over 24 hours 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP  over 24 hour time course at 37oC 
in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein expression via western 
blot. A)  Results were normalised by β-actin and displayed as mean ± SEM of triplicate experiments. 
Data is expressed as percentage of the respective control (cell only control) and significance is 
indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. 
B) Quantitative densitometry of western blots shows 150µM 7,8-NP decreasing CD36 expression 
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3.2.5 Recovery of CD36 expression after 7,8-NP removal 
Once the 7,8-NP induced down regulation of CD36 had been established the next step was 
to examine the recovery of CD36 after 7,8-NP removal. Investigation into the recovery of 
the cells after treatment is an important factor into the characterization of 7,8-NP’s effect 
on CD36. It also provides evidence as to whether or not cells are suitable for further 
experimentation after initial down regulation. Previous work examining the recovery of 
HMDMs after the removal of 7,8-NP was limited and only examined recovery up to a six 
hour time point (Schepetkina, 2013). Here we look at recovery up to 48 hours after 7,8-NP 
removal. U937 cells were incubated for 24 hours with 150µM 7,8-NP in a 75 cm3 cell 
culture flask in order to allow CD36 down regulation to take place. The cells were then 
centrifuged at 500x g to pellet the cells and the supernatant discarded to remove 7,8-NP. 
The cells were then re-suspended in fresh media before transfer into a 24 well suspension 
plate and incubated at 37oC. Cells were extracted from the wells at 0, 12, 24 and 48 hour 
time points and lysed in the presence of protease inhibitor and kept at -80oC until analysis. 
Once the time course was complete the cell lysate was then immunoblotted for the CD36 
protein with β-actin used as a loading control.  
The results show that after a 24 hour incubation period with 150µM 7,8-NP CD36 levels 
were down-regulated to a significant 50.22% of control (Figure 3.2.5). Recovery was then 
observed 12 hours after 7,8-NP removal where CD36 expression had recovered to a non-
significant 63.17% of control, and 24 hours after removal CD36 expression had recovered 
to a significant 96.02% of control. Between the 24 and 48 hour time points CD36 
expression began to decrease again to 30.91% of control at 48 hours. Recovery of CD36 
between the 12 and 24 hour time points, while showing that recovery does occur, limits 
time for any subsequent experimental work to between 0 and 12 hours after removal to 




















Figure 3.2.5 CD36 expression recovers 24 hours after 7,8-NP removal 
U937 cells (0.5x106 cells/mL) were treated 150µM 7,8-NP and incubated at 37oC over 24 hours in 
RPMI-1640 with phenol red to allow for down regulation to occur. 7,8-NP was then removed and 
the cells plated for an additional 48 hour time course. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of triplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots shows 7,8-NP CD36 
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3.2.6 Cellular viability of the recovery experiment 
During the recovery experiment the U937 cells underwent down regulation via 7,8-NP for 
24 hours before being plated for up to an additional 48 hours. The viability of this 
experiment was investigated at each time point to ensure that the results observed were not 
influenced by the loss of cellular viability over the experimental time course. At each time 
point (0, 12, 24 and 48 hours) prior to full cellular extraction and lysation, 50 µL of cells 
were taken from each well and incubated with 0.4% trypan blue at a ratio of 1:1 for 2 
minutes before viability analysis using a heamocytometer. Results showed that the recovery 
experiment had very little effect on cell viability (Figure 3.2.6). Viability immediately after 
7,8-NP removal was found to be at 96.37%. This level then held relatively steady over the 
entire time course with viability after 48 hours measured at 95.11%. No significant changes 
were observed between the different time points. 
Cells were also viewed under a light microscope at 20x magnification and images taken to 
observe morphological changes at each time point. Changes in cell morphology after 7,8-
NP induced down regulation and during recovery appear to be limited. Control cells show 
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Figure 3.2.6 CD36 expression recovers 24 hours after 7,8-NP removal 
U937 cells (0.5x106 cells/mL) were treated with 150µM of 7,8-NP at 37oC over 24 hours. 7,8-NP 
was then removed and cells incubated for a further 48 hour time course.  A) Cell viability was 
measured by tyrpan blue and the data was expressed as a percentage of the respective control (cell 
only control). Results are displayed as mean ± SEM of triplicates from a single experiment, 
representative of three separate experiments. Significance levels are indicated as: (*) p ≤ 0.05, (**) 
p ≤ 0.01 and (***) p ≤ 0.001. B. Images of U937 cells during each time point of recovery. B) Cells 
were viewed in tissue culture plates through an inverted microscope (20x magnification). The 
images were taken using a LEICA DMIL microscope with a LEICIA DFC290 camera. The 





3.2.7 Effect of neopterin on CD36 expression in the U937 cell line 
Neopterin is the oxidised product of 7,8-NP, and like 7,8-NP is also a member of the 
pteridine family. Biologically it can be used to provide information on cellular immune 
activation and as an inflammatory disease marker (Murr, Widner, Wirleitner, & Fuchs, 
2002). Once the down regulation effect of 7,8-NP was characterised in the U937 cell line 
it was of interest to measure any effect that neopterin may have on CD36 levels. To achieve 
this U937 cells were incubated with increasing levels of neopterin ranging from 0-100µM 
for 24 hours. Afterwards the cells were extracted from the wells and lysed. The cell lysate 
was then immunoblotted for the CD36 protein with β-actin used as a loading control. 
The results show that in the 0-100µM concentration range neopterin had no significant 
effect of CD36 expression compared to control levels (Figure 3.2.7). At 25µM & 75µM 
neopterin CD36 expression was 8.14% and 19.43% lower than control respectively, while 
at 50µM and 100µM CD36 expression was 6.50% and 12.29% higher than control. The 
fact that none of these changes were found to be significant or followed a discernible pattern 
indicates that unlike 7,8-NP, neopterin has no effect on CD36 expression. 
Cells were also viewed under a light microscope at 20x magnification and images taken to 
observe any morphological changes upon treatment. Changes in cell morphology during 
treatment with neopterin are limited with control cells showing a typical spherical 














































Figure 3.2.7 Neopterin has a limited effect on CD36 expression 
U937 cells (0.5x106 cells/mL) were treated with increasing concentrations of neopterin (0-100µM) 
at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of triplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots shows a limited effect on 
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Figure 3.2.8 Images of U937 cells after treatment with increasing concentrations of 
neopterin 
Images of U937 cells after treatment with increasing concentrations of neopterin for 24 hours. 
Cells were viewed in tissue culture plates through an inverted microscope (20x magnification). 
The images were taken using a LEICA DMIL microscope with a LEICIA DFC290 camera. The 
















3.3 Transcriptional control of CD36 
3.3.1 Effect of PPARγ inhibitor GW9662 on CD36 expression 
Previous publications have shown that CD36 is under control of a heterodimer formed 
between the nuclear receptors PPARγ and RXR (S. Han & Sidell, 2002). A kinase binding 
site located on the PPARγ component makes it a likely target for exploration into the 7,8-
NP induced down regulation pathway. Yet before this could commence it first had to be 
confirmed that CD36 was indeed under control of this heterodimer in the U937 cell line. 
To achieve this GW9662, an irreversible antagonist of PPARγ was chosen for use. GW9662 
selectively and covalently modifies the CYS285 residue of PPARγ, and is 10- and 600-fold 
less potent in binding experiments using PPARα and PPARδ isoforms (Leesnitzer et al., 
2002).  
U937 cells were incubated for 24 hours with increasing concentrations of GW9662 ranging 
from 0-15µM, with cells only used as a negative control and 150µM 7,8-NP as a positive 
control. At the 24 hour time point the cells were extracted and lysed. The cell lysate was 
then immunoblotted for the CD36 protein with β-actin used as a loading control. GW9662 
significantly decreased CD36 expression beginning at 5µM (66.47% of control) with a 
similar level of effect seen at 10µM (72.69% of control) (Figure 3.3.1). 15µM GW9662 
decreased CD36 expression further still (41.57% of control). Change compared to control 
was significant at all concentrations, being the most significant at 15µM. No significant 
changes were observed between the different concentrations. 150µM 7,8-NP alone 
decreased CD36 expression to 60.89% of control, comparable most to that seen with 5µM. 
The results confirm that CD36 is under control of PPARγ, and also our choice of PPARγ 



















Figure 3.3.1 PPARγ inhibitor GW9662 decreases CD36 expression 
U937 cells (0.5x106 cells/mL) were treated with increasing concentrations of GW9662 (0-15µM) 
at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of triplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots shows CD36 expression 
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3.3.2 Effect of GW9662 on cellular viability 
The PPARγ transcription factor alongside its role in CD36 regulation, is involved in 
controlling a wide variety of genes over several pathways related to lipid metabolism. These 
include fatty acid transport, catabolism and storage (Hardwick, Osei-Hyiaman, Wiland, 
Abdelmegeed, & Song, 2010). The use of the GW9662 inhibitor would interfere with these 
processes with a possible negative effect on cellular viability. To confirm the reliability of 
the results of the previous experiments cell viability was measured using the propidium 
iodide assay. This assay can determine the ratio of alive cells which have excluded the dye 
(PI negative) to non-viable cells (PI positive). Cells were incubated for 24 hours with 
increasing concentrations of GW9662 of between 5-15µM in RPMI-1640 without phenol 
red as the use of this colored pH indicator has the potential to interfere with assay results. 
Results show that all treatments had a limited effect on cellular viability with all GW9662 
concentrations used non-significantly reducing viability in a range of between 1.56-5.75% 
(Figure 3.3.2). The low impact that GW9662 had on viability, even at the higher 
concentrations, indicate cell viability loss was most likely not a factor in the GW9662 
triggered decrease in CD36 expression. 
Changes in cell morphology after GW992 treatment was examined using a light microscope 
(Leitz Wetzlab, Germany). Changes in cell morphology during treatment with GW9662 are 
limited with control cells showing a typical spherical morphology comparable with that 
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Figure 3.3.2 Effect of GW9662 on cellular viability using propidium iodide 
U937 cells (0.5x106) were treated with between 0-15µM GW9662 at 37oC over 24 hours in non-
phenol red RPMI-1640. A) Cell viability was measured by PI and the data was expressed as a 
percentage of the respective control (cell only control). Results are displayed as mean ± SEM of 
triplicates from a single experiment, representative of three separate experiments. Significance 
levels are indicated as: (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Images of U937 cells 
after treatment with increasing concentrations of GW9662 for 24 hours. Cells were viewed in tissue 
culture plates through an inverted microscope (20x magnification). The images were taken using a 
LEICA DMIL microscope with a LEICIA DFC290 camera. The population density is a 500,000 
cells per mL. 
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3.3.3 Effect of GW9662 in conjunction with 7,8-NP on CD36 expression 
Once it was confirmed that both 7,8-NP and GW9662 were able to down regulate observed 
levels of CD36, both were given in conjunction to U937 cells to determine if any additive 
effect on CD36 could be seen. To achieve this U937 cells were incubated for 24 hours with 
5µM GW9662 in combination with 150µM 7,8-NP. A 5µM concentration of GW9662 was 
chosen as this level was shown to down regulate CD36 levels to a similar extent as 150µM 
7,8-NP. GW9662 and 7,8-NP were also incubated with the cells in isolation to act as 
positive controls. At the 24 hour time point the cells were extracted from the wells and 
lysed. The cell lysate was then immunoblotted for the CD36 protein with β-actin used as a 
loading control. The results show that while both treatments down regulated observed 
CD36 levels to comparable levels, no additive effect could be seen. 7,8-NP in conjunction 
with GW9662 down regulated CD36 expression to 62.00% of control. This result is 
comparable to 7,8-NP (58.55%) and GW9662 alone (61.49%)  (Figure 3.3.3). This 
indicates that if 7,8-NP is having its effect via PPARγ that a maximum level of down 













































































Figure 3.3.3 GW9662 and 7,8-NP do not have an additive effect on 7,8-NP 
expression 
U937 cells (0.5x106 cells/mL) were treated with 5µM GW9662 in conjunction with 150µM 7,8-NP 
at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for CD36 protein 
expression via western blot. A) Results were normalised by β-actin and displayed as mean ± SEM 
of quadruplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, (**) p 
≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots shows no additive effect 
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3.3.4 Effect of increasing concentrations of cycloheximide on cellular 
viability 
Cycloheximide produced by the bacterium Streptomyces griseus acts as an inhibitor of 
protein synthesis in Eukaryotic organisms by interfering with the translocation process 
(Jones & Cushman, 1989). It is used in determining protein half-life via the use of time-
course experiments in conjunction with western-blotting to enable the detection of changes 
in protein bound signal over time. Due to its effect on protein synthesis the use of 
cycloheximide is likely to have an effect on cellular viability at higher levels that would 
confound any experimental results. In order to examine what levels are suitable for 
experimental work involving the U937 cell line a cell viability time course was examined 
using various concentrations of cycloheximide. U937 cells were incubated for 24 hours 
with increasing concentrations of cycloheximide ranging between 0-10µM in RPMI-1640 
without phenol red. At the 24 hour time point cells were extracted from cells and incubated 
with PI in the dark for 10 minutes before viability was measured. Results showed that 
increasing concentrations of cycloheximide had a negative effect on cellular viability 
(Figure 3.3.4). 2-5µM cycloheximide decreased viability in a range of 6.15-7.87% lower 
than control after 24 hours, however this decrease was non-significant. 10µM 
cycloheximide had a bigger impact, decreasing cellular viability to a significant 22.99% 
lower than that of control. No significant changes were observed between the different 
concentrations 
Changes in cell morphology after Cycloheximide treatment were examined using a light 
microscope (Leitz Wetzlab, Germany). U937 cells in the absence of cycloheximide showed 
a typical spherical morphology. Cells treated with 2µM cycloheximide appear lower in 
density but still display a healthy morphology albeit with a small amount of debris present. 
At 5µM continuing on to 10µM density decreased and cellular debris increased with 
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Figure 3.3.4 Effect of increasing concentrations of cycloheximide on cellular viability 
U937 cells (0.5x106 cells/mL) were treated with 0-10µM of cycloheximide at 37oC for 24 hours in 
non-phenol red RPMI-1640. A) Cell viability was measured by PI and the data was expressed as a 
percentage of the respective control (cell only control). Results are displayed as mean ± SEM of 
triplicates from a single experiment, representative of three separate experiments. Significance 
levels are indicated as: (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Images of U937 cells 
after treatment with increasing concentrations of cycloheximide for 24 hours. Cells were viewed in 
tissue culture plates through an inverted microscope (20x magnification). The images were taken 
using a LEICA DMIL microscope with a LEICIA DFC290 camera. The population density is a 





3.3.5 Effect of cycloheximide on CD36 expression 
After completion of the cell viability experiment a concentration of 1µM cycloheximide 
was decided as best suitable for use. Next a cycloheximide time course was undertaken in 
order to measure the natural half-life of CD36 and to explore whether 7,8-NP additionally 
has any effect on promoting CD36 degradation. 
U937 cells were plated in 24 well suspension plates and incubated with either 1) 150µM of 
7,8-NP, or 2) 150µM of 7,8-NP in conjunction with 1µM cycloheximide. After incubation 
cells were extracted from the wells at 0, 3, 6 and 9 hour time points, lysed in the presence 
of protease inhibitor and kept at -80oC until analysis. Once the time course was complete 
the cell lysate was then immunoblotted for the CD36 protein with β-actin used as a loading 
control. A 3 hour incubation with 1µM cycloheximide triggered a decrease in CD36 
expression to 83.61% of control levels while cycloheximide + 7,8-NP triggered a decrease 
to 73.61% of control levels. At 6 hours CD36 expression had further decreased with both 
cycloheximide, and cycloheximide + 7,8-NP (49.93% and 53.53% respectively). While at 
9 hours the detected CD36 levels were 32.91% and 36.19% respectively. Significance was 
detected for both cycloheximide, and cycloheximide + 7,8-NP treatments after 6 and 9 
hours of incubation but not at 3 hours. There was no significance between treatments at 
each respective time point. The results indicate that the half-life for CD36 is at around 6 
hours, and that as there was lack of any significant difference between the treatments, that 
7,8-NP is not enhancing the degradation of CD36 but rather is effecting CD36 transcription, 
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Figure 3.3.5 Effect of cycloheximide on CD36 expression 
U937 cells (0.5x106) were treated with 1µM of cycloheximide at 37oC over 12 hours in non-phenol 
red RPMI-1640. A) Results were normalised by β-actin and displayed as mean ± SEM of 
quadruplicate experiments. Data is expressed as percentage of the respective control (cell only 
control) and significance is indicated from this control. B) Quantitative densitometry of western 
blots shows the effect of 1µM of cycloheximide on the degradation of CD36 over 9 hours. C) 
Quantitative densitometry of western blots shows effect of cycloheximide + 7,8-NP on the 
degradation of CD36 over 9 hours.  Data is expressed as percentage of the respective control (cell 
only control) and significance is indicated from this control. Significance levels are: (*) p ≤ 0.05, 
(**) p ≤ 0.01 and (***) p ≤ 0.001.  
 
3.3.6 Cellular viability of the cycloheximide experiment 
During the 1µM cycloheximide time course the viability of this experiment was 
investigated at each time point to ensure that the results observed were not influenced by 
the loss of cellular viability. At each time point (0, 3, 6 and 9 hours) prior to full cellular 
extraction and lysation 50 µL of cells were taken from each well and incubated with 0.4% 
trypan blue at a ratio of 1:1 for 2 minutes before analysis using a heamocytometer. Results 
show both cycloheximide, and cycloheximide + 7,8-NP treatments had a limited effect on 
cellular viability over the 9 hour time course (Figure 3.3.6). 1µM cycloheximide decreased 
viability to a non-significant 6.86% lower than control by the 9 hour time point where as 
cycloheximide + 7,8-NP decreased viability to a similar 5.36 % of control. The results 
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Figure 3.3.6 Effect of cycloheximide and cycloheximide+7,8-NP on U937 cell 
viability using trypan blue 
U937 cells (0.5x106) were treated with 1µM of cycloheximide (A) or cycloheximide + 7,8-NP (B) 
at 37oC over 12 hours in non-phenol red RPMI-1640. Cell viability was measured by PI and the 
data was expressed as a percentage of the respective control (cell only control). Results are 
displayed as mean ± SEM of triplicates from a single experiment, representative of three separate 








Cycloheximide + 7,8-NP 
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3.4 Effect of MAP kinase inhibitors on CD36 down regulation 
3.4.1 Effect of JNK inhibition via SP600125 on 7,8-NP induced down 
regulation in the U937 cell line 
Phosphorylation of PPARγ leads to a decrease in its CD36 transcriptional activity which in 
turn lowers CD36 protein expression (Adams et al., 1997; Hu et al., 1996). This 
phosphorylation effect makes protein kinase pathways a possible target for 7,8-NP induced 
down regulation. PPARγ’s kinase site has been shown to recognise and bind two different 
MAP kinases, c-Jun N-terminal kinase (JNK) and extracellular signal–regulated kinases 
1/2 (ERK1/2). To explore the effect on inhibiting the JNK MAP kinase pathway on CD36 
expression the cell permeable and selective inhibitor SP600125 was used. SP600125 works 
by competing with JNK’s ATP binding site which halts the flow of the kinase cascade, thus 
preventing the signal from progressing (Bennett et al., 2001). U937 cells where pre-
incubated with 50µM SP600125 in a 24 well suspension plate. 150µM 7,8-NP in 
conjunction with SP600125 was additionally added to determine whether inhibiting JNK 
could block 7,8-NP induced CD36 down regulation. 150µM 7,8-NP alone was used as a 
positive control and cells only as a negative control. At the 24 hour time point cells were 
extracted and lysed in the presence of a protease inhibitor. Cell lysate was immunoblotted 
for CD36 with β-actin used as a loading control.  
Results showed that SP600125 did not block 7,8-NP’s effect on CD36 expression but rather 
was able to decrease CD36 expression to 32.65% of control alone (Figure 3.4.1). This 
decrease was more pronounced than that of the 7,8-NP control which down regulated CD36 
expression to 64.86% of control. When given in conjunction SP600125 and 7,8-NP lowered 




















































































Figure 3.4.1 JNK inhibition via SP600125 does not block CD36 down regulation 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 50µM of SP600125, and both in 
conjunction at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for 
CD36 protein expression via western blot. A) Results were normalised by β-actin and displayed as 
mean ± SEM of triplicate experiments. Data is expressed as percentage of the respective control 
(cell only control) and significance is indicated from this control. Significance levels are: (*) p ≤ 
0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots showed that 
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3.4.2 Effect of JNK inhibition on cellular viability 
JNK kinase cascades are involved in mediating the cellular apoptotic response to pro-
inflammatory cytokines, genotoxins and environmental stress, along with having a role in 
the regulation of cell proliferation, survival and differentiation (C. Davies & Tournier, 
2012). Use of the SP600125 inhibitor would interfere with these processes with possible 
negative effects on cellular viability. To confirm the reliability of the results of the previous 
experiment cell viability was measured using the propidium iodide assay. Cells were 
incubated for 24 hours with 50µM SP600125, along with 50µM SP600125 in conjunction 
with 150µM 7,8-NP, 150µM 7,8-NP alone and a cell only control. At the 24 hour time 
point cells were extracted and cell viability measured by PI using flow cytometry. 
Results show that at 50µM SP600125 had a limited effect on U937 cellular viability. After 
a 24 hour incubation viability decreased to 7.16% lower than that of control (Figure 3.4.2). 
Even though this decrease was found to be significant, the low level of change means that 
it was unlikely to have had a major impact on the observed results. In contrast after 
incubation with 150µM 7,8-NP viability was 1.37% lower than control, and 7,8-NP + 
SP600125 in combination 3.41% lower than control. 
Changes in cell morphology after SP600125 treatment was examined using a light 
microscope (Leitz Wetzlab, Germany). Changes in cell morphology during treatment with 
SP600125 are non-existent with all cellular treatments showing a typical healthy 
morphology (Figure 3.4.2B). In treatments with SP600125 sharp yellow strands can be 
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Figure 3.4.2 Effect of SP600125 on U937 cell viability using propidium iodide 
U937 cells (0.5x106) were treated with 150µM 7,8-NP, 50µM of SP600125 and both in conjunction 
at 37oC over 24 hours in non-phenol red RPMI-1640. A.) Cell viability was measured by PI and the 
data was expressed as a percentage of the respective control (cell only control). Results are 
displayed as mean ± SEM of triplicates from a single experiment, representative of three separate 
experiments. Significance levels are indicated as: (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. 
B) Images of U937 cells after treatment with 150µM 7,8-NP, 50µM of SP600125 and both in 
conjunction for 24 hours. Cells were viewed in tissue culture plates through an inverted microscope 
(20x magnification). The images were taken using a LEICA DMIL microscope with a LEICIA 





3.4.3 Effect of MEK inhibition via PD98059 on 7,8-NP induced down 
regulation in the U937 cell line 
PPARγ’s kinase site, alongside recognising JNK, has also been shown to recognise and 
bind the ERK1/2 MAP kinase (Burns, 2007). To explore the effect on inhibiting the 
ERK1/2 MAP kinase pathway on CD36 expression the inhibitor PD98059 was used. 
PD98059 has its effect by selectively inhibiting the MAP kinase kinases MEK1 and MEK2 
by binding to their inactive form (S. P. Davies, Reddy, Caivano, & Cohen, 2000). This 
prevents any activators from binding and effectively blocks downstream activation of 
ERK1/2 and the signalling cascade. U937 cells where pre-incubated with 25µM PD98059 
before 150µM 7,8-NP was added to selected wells to determine whether inhibiting the 
ERK1/2 pathway could block 7,8-NP induced CD36 down regulation. 150µM 7,8-NP in 
isolation was used as a positive control and cells only as a negative control. At the 24 hour 
time point cells were extracted, washed in PBS and lysed in the presence of a protease 
inhibitor. Cell lysate was immunoblotted for CD36 with β-actin used as a loading control. 
Results show that PD98059 did not block 7,8-NP’s effect on CD36 expression (Figure 
3.4.3).  150µM 7,8-NP was found to significantly reduce CD36 expression to 41.20% of 
control, while 7,8-NP in conjunction with PD98059 reduced expression to a similar 48.66% 
of control. The differences between these two treatments were non-significant indicating 
that 7,8-NP does not down-regulate CD36 expression via ERK1/2. PD98059 treatment 
alone did not have a major effect on CD36 expression non-significantly reducing levels to 





















Figure 3.4.3 MEK inhibition via PD98059 does not block CD36 down regulation 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 25µM of PD98059 and both in 
conjunction at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for 
CD36 protein expression via western blot. A) Results were normalised by β-actin and displayed as 
mean ± SEM of triplicate experiments. Data is expressed as percentage of the respective control 
(cell only control) and significance is indicated from this control. Significance levels are: (*) p ≤ 
0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots showed that 
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3.4.4 Effect of MEK inhibition on cellular viability  
ERK1/2 cascades are involved in a wide variety of cellular functions including in adhesion, 
progression, migration, survival, differentiation, metabolism, proliferation, and 
transcription (Roskoski, 2012). Use of the PD98059 inhibitor would interfere with these 
processes with possible negative effects on cellular viability.  To confirm the reliability of 
the results of the previous experiment cell viability was measured using the trypan blue 
assay. Cells were incubated for 24 hours with either 25µM PD98059, 25µM PD98059 in 
conjunction with 150µM 7,8-NP, 150µM 7,8-NP alone or a cell only control. At the 24 
hour time point 50 µL of cells were taken from each well and incubated with 0.4% trypan 
blue at a ratio of 1:1 for 2 minutes before analysis using a heamocytometer. Results show 
that at 25µM PD98059 had a limited effect on U937 cellular viability. After a 24 hour 
incubation viability had decreased to 0.67% lower than control (Figure 3.4.4). In contrast 
150µM 7,8-NP viability was 1.33% higher than control and the two in combination 0.94% 
lower than control. 
Changes in cell morphology after PD98059 treatment was examined using a light 
microscope (Leitz Wetzlab, Germany). Changes in cell morphology during treatment with 
PD98059 are non-existent with all cellular treatments showing a typical healthy 
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Figure 3.4.4 Effect of PD98059 on U937 cell viability using trypan blue 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 25µM of PD98059 and both in 
conjunction at 37oC over 24 hours in non-phenol red RPMI-1640. A) Cell viability was measured 
by trypan blue and the data was expressed as a percentage of the respective control (cell only 
control). Results are displayed as mean ± SEM of triplicates from a single experiment, 
representative of three separate experiments. Significance levels are indicated as: (*) p ≤ 0.05, (**) 
p ≤ 0.01 and (***) p ≤ 0.001. B) Images of U937 cells after treatment with 150µM 7,8-NP, 50µM 
of PD98059  and both in conjunction for 24 hours. Cells were viewed in tissue culture plates through 
an inverted microscope (20x magnification). The images were taken using a LEICA DMIL 
microscope with a LEICIA DFC290 camera.  
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3.4.5 Effect of p38 inhibition via SB202190 on 7,8-NP induced down 
regulation in the U937 cell line 
Alongside the JNK and ERK1/2 kinases several other MAP kinases are involved in cell 
signalling and are candidates for involvement in 7,8-NP induced down regulation. The p38 
MAP kinase and its signalling cascades are activated by stress and play a role in immune 
response, cellular survival and differentiation (Cuadrado & Nebreda, 2010). To explore the 
role of p38 in relation to 7,8-NP and CD36 the p38 inhibitor SB202190 was used. 
SB202190 is a selective, potent and cell permeable inhibitor of the p38 MAP kinase 
including both p38α and β isoforms. It works by binding within the ATP pocket of the 
active kinase preventing further signal transduction (S. P. Davies et al., 2000). 
U937 cells where pre-incubated with 20µM SB202190 before 150µM 7,8-NP was added 
to selected wells to determine whether p38 inhibition could block 7,8-NP induced CD36 
down regulation. 150µM 7,8-NP in isolation was used as a positive control and cells only 
as a negative control. At the 24 hour time point cells were extracted and lysed. Cell lysate 
was immunoblotted for CD36 with β-actin used as a loading control.  
Results show that SB202190 did not block 7,8-NP’s effect on CD36.  Rather like SP600125 
it was able to decrease CD36 expression alone (Figure 3.4.5). This decrease was found to 
be 42.32% of control, slightly less than that of 7,8-NP which down regulated CD36 
expression to 55.37% of control. When given in conjunction SB202190 and 7,8-NP 
lowered CD36 expression to 30.71% of control, which although is a larger decrease, was 
not significant compared to the two in isolation. All results were found to be significant in 



















































































Figure 3.4.5 p38 inhibition via SB202190 does not block CD36 down regulation 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 20µM of SB202190 and both in 
conjunction at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for 
CD36 protein expression via western blot. A) Results were normalised by β-actin and displayed as 
mean ± SEM of triplicate experiments. Data is expressed as percentage of the respective control 
(cell only control) and significance is indicated from this control. Significance levels are: (*) p ≤ 
0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots showed that 
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3.4.6 Effect of p38 inhibition on cellular viability 
Due to the various roles that p38 plays in cellular signalling it is possible that the use of 
SB202190 would have an effect of cellular viability. To confirm the reliability of the results 
of the previous experiment cell viability was measured using the propidium iodide assay. 
Cells were incubated for 24 hours with either 20µM SB202190, 20µM SB202190 in 
conjunction with 150µM 7,8-NP, 150µM 7,8-NP alone or a cell only control. At the 24 
hour time point cells were extracted and cell viability measured by propidium iodie using 
flow cytometry. Results show that 20µM SB202190 has a limited effect on U937 cellular 
viability. After a 24 hour incubation viability had non-significantly decreased to 2.02% 
lower than control (Figure 3.4.6). In contrast with the 150µM 7,8-NP treatment viability 
was 1.37% lower than control and with the two in combination viability was 2.26% lower 
than control.  
Changes in cell morphology after GW992 treatment was examined using a light microscope 
(Leitz Wetzlab, Germany). Changes in cell morphology during treatment with SB202190 
were limited with control cells showing a typical spherical morphology comparable to that 
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Figure 3.4.6 Effect of SB202190 on U937 cell viability using propidium iodide 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 20µM of SB202190 and both in 
conjunction at 37oC over 24 hours in non-phenol red RPMI-1640. A) Cell viability was measured 
by PI and the data was expressed as a percentage of the respective control (cell only control). Results 
are displayed as mean ± SEM of triplicates from a single experiment, representative of three 
separate experiments. Significance levels are indicated as: (*) p ≤ 0.05, (**) p ≤ 0.01 and (**) p ≤ 
0.001. B) Images of U937 cells after treatment with 150µM 7,8-NP, 20µM of SB202190 and both 
in conjunction for 24 hours. Cells were viewed in tissue culture plates through an inverted 
microscope (20x magnification). The images were taken using a LEICA DMIL microscope with a 






3.4.7 Effect of NF-kB inhibition via BAY 11-7082 on 7,8-NP induced 
down regulation in the U937 cell line 
MAP kinases are not alone in the mediation of cellular signalling. NF-kB signalling has 
been shown to be present in macrophages, and is involved in the transcription of numerous 
cytokines which play a role in cell growth and differentiation (Brasier, 2006). It was of 
interest here to explore the role of NF-kB inhibition on CD36 expression and whether this 
would have any effect on 7,8-NP induced down regulation. To achieve this U937 cells 
where pre-incubated with 2µM BAY 11-7082 before 150µM 7,8-NP was added to selected 
wells to measure whether NF-kB inhibition could block 7,8-NP induced CD36 down 
regulation. 150µM 7,8-NP in isolation was used as a positive control and cells only as a 
negative control. At the 24 hour time point cells were extracted and lysed in the presence 
of a protease inhibitor. Cell lysate was immunoblotted for CD36 with β-actin used as a 
loading control.  
Results show that 2µM BAY 11-7082 did not alleviate 7,8-NP’s effect on CD36 expression 
(Figure 3.4.7).  150µM 7,8-NP was found to significantly reduce CD36 expression to 
53.66% of control, while 7,8-NP in conjunction with 1µM BAY 11-7082  reduced 
expression to a similar 62.34% of control. The differences between these two treatments 
were non-significant indicating that 7,8-NP did not down-regulate CD36 expression via 
NF-kB. 2µM BAY 11-7082 treatment alone was found to have an effect on CD36 
expression with a significant reduction to 55.55% of control, similar to what was seen with 

























Figure 3.4.7 NF-kB inhibition via BAY 11-7082 does not alleviate CD36 down 
regulation 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 2µM of BAY 11-7082 and both in 
conjunction at 37oC over 24 hours in RPMI-1640 with phenol red. Cell lysate was assessed for 
CD36 protein expression via western blot. A) Results were normalised by β-actin and displayed as 
mean ± SEM of triplicate experiments. Data is expressed as percentage of the respective control 
(cell only control) and significance is indicated from this control. Significance levels are: (*) p ≤ 
0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. B) Quantitative densitometry of western blots showed that 
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3.4.8 Effect of NF-kB Inhibition on cellular viability 
NF-kB plays an important role in the mediation of stress responses and inflammation. Use 
of the BAY 11-7082 inhibitor would interfere with these processes with possible negative 
effects on cellular viability. To confirm the reliability of the results of the previous 
experiment cell viability was measured using the propidium iodide assay. Cells were 
incubated for 24 hours with 2 µM BAY 11-7082, along with 2µM BAY 11-7082 in 
conjunction with 150µM 7,8-NP, 150µM 7,8-NP alone and a cell only control. At the 24 
hour time point cells were extracted and cell viability measured by PI using flow cytometry. 
Results show that 2µM BAY 11-7082 has a limited effect on U937 cellular viability after 
a 24 hour incubation in which viability had non-significantly decreased to 3.19% lower 
than control (Figure 3.4.8). In contrast with the 150µM 7,8-NP treatment viability was 
1.37% lower than control and the two in combination 2.80% lower than control. 
Changes in cell morphology after BAY 11-7082 treatment was examined using a light 
microscope (Leitz Wetzlab, Germany). Changes in cell morphology during treatment with 
BAY 11-7082 were limited with control cells showing a typical spherical morphology 
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Figure 3.4.8 Effect of BAY 11-7082 on U937 cell viability using propidium iodide 
U937 cells (0.5x106 cells/mL) were treated with 150µM 7,8-NP, 2 µM of BAY 11-7082 and both 
in conjunction at 37oC over 24 hours in non-phenol red RPMI-1640. A) Cell viability was measured 
by PI and the data was expressed as a percentage of the respective control (cell only control). Results 
are displayed as mean ± SEM of triplicates from a single experiment, representative of three 
separate experiments. Significance levels are indicated as: (*) p ≤ 0.05, (**) p ≤ 0.01 and (**) p ≤ 
0.001. ) Images of U937 cells after treatment with 150µM 7,8-NP, 2µM of BAY 11-7082 and both 
in conjunction for 24 hours. Cells were viewed in tissue culture plates through an inverted 
microscope (20x magnification). The images were taken using a LEICA DMIL microscope with a 
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3.5 CD36 flow cytometry 
3.5.1 CD36 flow cytometry protocol design 
Once CD36 down regulation had been characterised using western blotting the effect of 
7,8-NP on  CD36 surface expression in whole cells was examined using flow cytometry. 
Prior to this the effectiveness of the anti-CD36 antibody and PE labelled secondary 
antibody had to be re-determined after successful previous use in U937 cells and HMDMs 
(S. Davies, 2015). It was previously found that 10μg/mL of primary anti-CD36 antibody 
was the most effective concentration and this was re-examined here. U937 cells were 
treated in the dark, on ice with 10μg/mL of CD36 antibody, a primary, or a secondary 
antibody control for 30 minutes. Cells were then suspended in 1mL PBS and BSA as per 
method and run through the flow cytometer using the FL2 filter which measured the 
fluorescence at 572 nM. 
It was found the protocol used was reliable in detecting the CD36 bound antibody. Only 
one population was found to be present as expected when using an identical cell line 
(Figure 3.5.1.1). The presence of only one population means that any signal can be 
measured consistently due to the lack of interference from other cell populations. The 
second smaller cluster of cells is likely cellular debris. When gated in FL-2 all antibody 
controls emissions either had no (Cell only, 10) or very limited (20) overlap with the anti-
CD36 signal. This indicates that 10μg/mL of primary antibody is an effective concentration 
to exclusively detect a strong CD36 signal. (Figure 3.5.1.2) shows a histogram along with 












Figure 3.5.1.1 Flow cytometer traces for CD36 antibody on U937 cells 
U937 cells (0.5x106 cells/mL) were incubated with anti-CD36 primary and secondary antibodies as 
per method for 30 minutes before being processed by flow cytometry. Cell only, and 10 and 20 
antibody controls were also used. A,D,G,J) indicates the presence of one dominant population of 
cells following incubation. E-F,H-I) show the position of FL-2 emission peak in the various 
controls. K & L) show that a strong anti CD36 signal was exclusively detected using 10µg/mL 
antibody.  
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Figure 3.5.1.2 Use of the flow cytometry CD36 antibody on the U937 cell line 
U937 cells (0.5x106 cells/mL) were incubated with anti-CD36 primary and secondary antibodies as 
per method for 30 minutes before being processed by flow cytometry. Cell only, and 10 and 20 
antibody controls were also used. Whole cells were assessed for CD36 protein expression via flow 
cytometry A) FL-2 emission signal after treatment transformed into a histogram. B) Analysis of 





3.5.2 Down regulation of CD36 detected via flow cytometry 
After confirmation of the flow cytometry protocol the effect of 7,8-NP on CD36 surface 
expression in whole cells was examined using flow cytometry. To achieve this U937 cells 
were incubated for 24 hours with 7,8-NP in concentrations ranging from 0-150µM. At the 
24 hour time point the cells were extracted and treated in the dark, on ice with 10μg/mL 
of a CD36 antibody, a primary, or a secondary antibody control for 30 minutes. Cells 
were then suspended in 1mL PBS and BSA as per method and run through the flow 
cytometer using the FL2 filter. 
Results show that as the concentration of 7,8-NP increased the mean signal detected when 
gated in FL-2 decreased (Figures 3.5.2.1 & 3.5.2.2). At 50µM 7,8-NP mean FL-2 was 
88.22% of control. The signal decreased further at 100µM (71.371%) and at 150µM 
(53.23%). The results indicate that 7,8-NP induced down regulation could be detected 
using flow cytometry, although not at the significance levels observed using western 
bolting. (Figure 3.5.2.1) also shows that as the mean FL-2 shifts towards the lower end of 
the spectrum a second population FL-2 gated cells can be seen. The shift does not 
correspond to second type of cell being present as only one population is still observed 
using forward and side scatter analysis. This indicates the difference in FL-2 gated 
emission comes from 7,8-NP having an effect on CD36 antibody binding to U937 cells 
due its presence and not an additional source. (Figure 3.5.2.2) shows a corresponding 
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Figure 3.5.2.1 Flow cytometer traces for increasing concentrations of 7,8-NP  on 
U937 cells 
U937 cells (0.5x106 cells/mL) were treated with 0-150µM 7,8-NP and incubated at 37oC over a 24 
hour time course. Whole cells were assessed for CD36 protein expression via flow cytometry. 
A,D,G,H) Indicates the presence of one dominant population of cells following incubation. B-
C,E-F,H-I,K-L) Shows a decreasing emission signal at 572 nM as 7,8-NP concentration increases. 
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Figure 3.5.2.2 Effect of 7,8-NP on U937 cells detected using flow cytometry 
U937 cells (0.5x106) were treated with 0-150 µM 7,8-NP and incubated at 37oC over a 24 hour 
time course. Whole cells were assessed for CD36 protein expression via flow cytometry A) FL-2 
emission signal after treatment transformed into a histogram showing two distinct populations. B) 









4.1 Characterising CD36 down regulation 
It was found that in the U937 cell line 7,8-NP down regulated CD36 in a concentration 
dependant manner beginning at 50µM and continuing to 150µM (Figure 3.2.1). Noticeably 
the down regulation observed here was to a higher extent and occurred at lower 
concentrations compared to that previously seen when using human monocyte derived 
macrophages (HMDM) (Gieseg et al., 2010). This current research also explored the rate 
at which 7,8-NP had its down regulation effect on CD36 which begun at 6 hours and 
continued on to the 24 hour time point (Figure 3.2.2). Such rapid down regulation was 
again not seen previously in HMDMs. These results suggest that 7,8-NP has a much 
stronger effect on U937 cells compared to HMDMs. A possible explanation for these 
discrepancies may be related to the inherent differences between monocytes and 
differentiated macrophages. Macrophages by nature are a lot bigger in size and it may be 
that the ratio of 7,8-NP to cell size has to be necessarily higher here in order to get the same 
result. It may also be that there are differences in the quantity of the 7,8-NP receptor 
between the cell types, and that it is differences in receptor-ligand binding that account for 
the increased effect seen in the U937 cell line. In the U937 cells 7,8-NP has been shown to 
enter the cell by the equilibrative nucleoside transporter 2 (ENT-2), whereas both ENT's 
and concentrative nucleoside transporters (CNT) are involved in 7,8-NP uptake in human 
monocytes, which may correlate to human macrophages (Janmale, 2013). Additionally it 
may be that the CD36 transcription is more sensitive to the effect of 7,8-NP in monocyte 
like cell systems. 
Shchepetkina (2013) briefly also looked at the relationship between U937’s and 7,8-NP. 
However in comparison to the current research this relationship was not explored in depth. 
Schepetkina found previously that while the active band of CD36 was down regulated in 
the U937 cell line, the results were non-significant. A possible explanation for this 
discrepancy may be related to the basal intensities of CD36 in the cell batches used. In 
Shchepetkina’s research the CD36 band observed was much less compared to that seen in 
the present study, even though the same mature band was analysed. A result of this could 
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be that a strong 7,8-NP effect may not have been possible to be detected. Evidence for this 
theory derives from one stage of the current research in which a fresh batch of U937 cells 
was brought up from storage that showed very little CD36 expression, and with 7,8-NP 
having no detectable effect. Upon examination it was found that this batch was much older 
compared to the prior batch used. It is possible that work the Shchepetkina (2013) 
undertook using the U937 cell line used a similar lower expressing batch which would 
explain the discrepancies in basal CD36 levels and the dampened effect of 7,8-NP. 
To further characterise the effect of 7,8-NP it was of interest to explore if CD36 levels are 
able to recover after initial down regulation, and if so at what rate. This would allow for the 
use of the U937 cell line in treatments exploring the consequences of 7,8-NP down 
regulation along with examining any effects after recovery. Recovery was found to occur 
reasonably fast once 7,8-NP had been removed from the media with CD36 expression 
beginning to recover at 12 hours and nearing control levels 24 hours after removal (Figure 
3.2.5). This result shows that future experimentation can be undertaken on U937 cells that 
have had their CD36 down regulated while still being viable. Of possible concern may be 
that full down regulation was not observed and that the rate of CD36 recovery limits the 
time frame for any experimentation to ensure CD36 levels are still down regulated. It is 
also of note that between the 24 and 48 hour time points CD36 expression began to decrease 
once again. This decrease did not correlate to loss of cellular viability (Figure 3.2.6). It is 
possible that the time course length by this point, totalling 48 hours, was having an impact 
and facilitating the cellular release of signals into the media that were impacting CD36 
expression. Future experimentation will need to to examine what happens between the 24 
and 48 hour time points. A possible remedy may be the replacement of cell media during 
recovery. At the point of writing it seems that this is the first research looking into the 
recovery of CD36 after down regulation limiting any comparison of these results. 
In addition to examining the effect of 7,8-NP on CD36, the oxidised form of this pterin, 
neopterin, was also looked at (Figure 3.2.7). It was found that in the U937 cell line 
neopterin had no significant effect on CD36 expression. This result compares well to those 
of Shchepetkina (2013) who found that likewise neopterin had no significant effect on 
CD36 levels in HMDM cells. This suggests that a specific 7,8-NP property, and not a 
general pteridine effect, is likely responsible for CD36 down regulation. Yet other 
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pteridines such as xanthopterin and biopterin were not examined during this research and 
it would be of further interest to examine their effect on CD36 to fully confirm this 
statement. 
Overall the results here comprehensively show that 7,8-NP will down regulate CD36 in the 
U937 cell line, and has its effect at lower concentrations and at a faster rate compared to 
HMDMs. This supports their use in the current research exploring the relationship between 
7,8-NP and CD36 with the aim of describing a possible mechanism of action. 
4.2 CD36 down regulation measured via flow cytometry 
The western blotting protocol used in this thesis measured CD36 levels using cell lysate, 
specifically looking at the mature CD36 band located on the cell surface of U937s. The 
nature of western blotting required the cells to by fully lysed in order to separate out their 
proteins for antibody probing, consequently rendering the cells non-viable in the process. 
Flow cytometry was used as an alternative method to overcome this issue and enabled the 
anti-CD36 antibody to bind to the actual cell surface CD36 of whole cells. 
Flow cytometry was considered an appropriate technique to use as changes in CD36 
expression has previously been measured in monocyte cells using these protocols. Viana et 
al. (2005) showed a dose dependent increase in CD36 expression when THP-1’s were 
incubated in medium containing water soluble aldehydes and a significant reduction when 
they were incubated with α-tocopherol. While Carvalho et al. (2010), also using flow 
cytometry, demonstrated that HDL reduced measured CD36 levels in the U937 cell line 
after stimulation with with oxLDL. 
In the current research while a significant 7,8-NP induced CD36 down regulation event 
was observed using cell lysate, the same results were not seen when using flow cytometry. 
While a concentration depended down regulation was observed, the results after analysis 
were non-significant (Figure 3.5.1). This was not expected as the mature CD36 band 
analysed during the western blotting experiments is thought to correspond to cell surface 
CD36 (Alessio et al., 1996). One possible reason for this discrepancy may be related to the 
recycling system a cell uses to replenish protein. There is a large amount of CD36 present 
in vacuoles that is not transported to the cell surface until required for protein turnover 
(Febbraio & Silverstein, 2007; Huh, Pearce, Yesner, Schindler, & Silverstein, 1996). It is 
93 
 
possible that the differences in the effect seen may be related to this as vacuole contained 
protein would have been available after lysis for anti-body binding but not in whole cells. 
Davies (2015) also using flow cytometry was able to measure the effect of 7,8-NP on CD36 
using HMDMs. A small but significant reduction in CD36 was observed after a 24 hour 
incubation with 200µM 7,8-NP. Similar to U937s there were discrepancies between the 
flow cytometry results here and the effect that Shchepetkina (2013) found with HMDMs 
using western blotting. The combined results of this and the current work indicates that the 
overall sensitivity of the flow cytometry protocol is likely less compared to western 
blotting, and that if the viability of cells after analysis is not of concern, western blotting 
should be the favoured protocol to ensure a stronger measured effect. 
4.3 Transcriptional control of CD36 
After confirming 7,8-NPs effect on CD36 in the U937 cell line the primary aim of this 
research was to describe the mechanism of its action. The first step here was to confirm 
what was under the transcriptional control of CD36 to ensure research into the appropriate 
system. While CD36 mRNA levels were not explored in this current research an impact on 
CD36 protein expression was thought likely to be the cause of 7,8-NP’s effect. This is due 
to research previously undertaken in the Free Radical Laboratory that showed that 
incubation with 7,8-NP significantly reduced the expression of CD36 mRNA in HMDM 
cells, pointing to an effect on CD36 transcriptional control (Shchepetkina, 2013).  
Studies have shown that CD36 transcription is controlled by the heterodimer Peroxisome 
Proliferator Activated Receptor-γ/Retinoid X Receptor (PPARγ/RXR) (Han & Sidell, 
2002; Tontonoz et al., 1998). This was confirmed in U937 cells via their incubation with 
the specific PPARγ inhibitor GW9662. Inhibition of PPARγ decreased in CD36 expression 
levels in a concentration dependant manner similar to what was seen after incubation with 
7,8-NP (Figure 3.3.1).  
This result correlated well to the experimental literature. Chen, Li, Wang, Wen, and Sun 
(2009) in research using differentiated L6 myotubes showed that incubation with GW9962 
resulted in a decrease in basal CD36 levels to 64% of control. Lee et al. (2009) found that 
resistin up-regulation of CD36 mediated by PPARγ was rescued by incubation with 
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GW9662, and Flores et al. (2016) demonstrated that CD36 and PPARγ stimulated with the 
ligand 15d-PGJ2 was able to be inhibited by GW9662.  
While it is the hypothesis of this thesis that 7,8-NP down regulates CD36 expression via 
interaction with the PPARɣ transcription factor, the use of the PPARɣ inhibitor did not 
necessarily confirm that 7,8-NP fully has its effect by preventing transcription. It is possible 
that 7,8-NP additionally has an effect down-stream of transcription and lowers CD36 levels 
by enhancing the degradation of this protein. Experiments with cycloheximide provided 
evidence that this is not the case. Cycloheximide produced by the bacterium Streptomyces 
griseus acts as an inhibitor of protein synthesis in Eukaryotic organisms by interfering with 
the translocation process (Jones & Cushman, 1989) meaning any protein loss subsequently 
observed is due to degradation of existing protein. A decrease in CD36 levels was found 
when U937 cells were incubated with both cycloheximide, and cycloheximide in 
conjunction with 7,8-NP. Importantly down regulation under both treatments occurred at 
the same rate (Figure 3.3.5). It would have been expected that if 7,8-NP was having its 
effect by enhancing the degradation of CD36 that 7,8-NP incubation alongside 
cycloheximide would have had a much more significant impact on CD36 levels than 
incubation with cycloheximide alone. This not being the result provided strong evidence 
that 7,8-NP is indeed having its effect on CD36 during the transcriptional process. The 
results of the cycloheximide experiment additionally supplied information on the half-life 
of CD36 which was determined at being ~6 hours.  
A variety of published research is available that also looked at the effect of cycloheximide 
on CD36 expression, but there is a wide discrepancy in the results that appears to be related 
to the cell line used. In J774A.1 macrophages 1µg/mL cycloheximide decreased CD36 
expression to under 50% of control after 1 hour (Yun et al., 2008). This is a much faster 
rate than that observed in the current research using U937 cells. Yet using a different type 
of macrophage (RAW264.7 macrophages) Yang et al. (2015) found a much slower rate 
using 5µM cycloheximide in which CD36 expression had decreased to ~60% of control 
after 16 hours. In human peripheral blood mononuclear cells, 1µg/mL cycloheximide 
diminished CD36 expression to around 50% of control after 48 hours (Malfitano et al., 
2007), while Mwaikambo, Yang, Chemtob, and Hardy (2009) demonstrated that in human 
retinal pigment epithelial cells CD36 expression was found to be ~70% of control after 4 
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hours when incubated with 25µM cycloheximide. The large variability displayed between 
these results and what was found using the U937 cell line can possibly be explained by the 
inherent differences in the cell types used such as the size of the cell, differentiation state, 
the basal levels of CD36 present, along with the permeability of cycloheximide. 
4.4 The effect of MAP kinase inhibitors 
The results of this research indicated that 7,8-NP is likely having its effect on CD36 via 
interfering with the PPARγ transcription factor. The regulatory process of PPARγ is 
complex with it containing both ligand and kinase binding sites which can either enhance 
or inhibit transcriptional activity (Adams et al., 1997; Feng et al., 2000; Hu et al., 1996). 
PPARγ also forms a heterodimer with RXR which itself can bind certain unsaturated fatty 
acids collectively termed rexnoids which have been shown to include docosahexaenoic 
acid, arachidonic acid and oleic acid (Dawson & Xia, 2012; Lengqvist et al., 2004). In 
terms of 7,8-NP’s mechanism of action it was thought that a MAP kinase mediated pathway 
was the most likely responsible for inhibiting CD36 transcription. It has been well 
established that the PPARγ kinase binding site recognises both the ERK1/2 and JNK 
kinases and that phosphorylation here is unusual in that it mediates a decrease in CD36 
transcriptional activity (Adams et al., 1997; Hu et al., 1996). As such MAP kinases became 
the main focus of this thesis. Surprisingly it was found that inhibition of JNK and ERK1/2 
kinases failed to rescue the effect of 7,8-NP, along with inhibition of additional p38 and 
NF-κB signalling pathways. While unexpectedly JNK, p38 and NF-κB inhibition alone 
down regulated CD36 levels. 
4.4.1 JNK inhibition 
Evidence that JNK kinase mediated a decrease in PPARγ activity initially came from 
transfected cell studies. JNK kinase negatively regulated the transcriptional activity of 
human embryonic kidney cells transfected with mouse PPARγ via a PPARγ 
phosphorylation event (Camp & Tafuri, 1997), while a study by Adams et al. (1997) 
showed the same effect in JEG-3 cells transfected with human PPARγ.  
It would have been expected that if 7,8-NP was having its effect on CD36 via activation of 
a JNK kinase cascade that the use of the specific JNK inhibitor SP600125 would have 
blocked any down regulation. This was found not to be the case. While co-incubation of 
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7,8-NP with SP600125 lead to a slight rescue of CD36 expression, this was non-significant 
and importantly U937 incubation with SP600125 alone caused a large and significant 
decrease in CD36 (Figure 3.4.1). The viability experiments showed that the CD36 decrease 
was not the result of lost viability (Figure 3.4.2). Instead it appears that in model cell 
systems JNK mediated phosphorylation is not necessarily always responsible for a decrease 
in PPARγ transcriptional activity. Similar to the results found in this thesis, Huang et al. 
(2016) showed SP600125 treatment in the THP-1 cell line resulted in a decrease in basal 
levels of CD36, while also decreasing CD36 levels after oxLDL induced upregulation. A 
SP600125 mediated decrease in basal CD36 levels was also observed in research by Li, 
Kong, Li, He, and Zhou (2013) in THP-1 derived macrophages. Other cell systems have 
also found comparable results to what was observed using U937’s. In RAW264.7 
macrophages JNK inhibition reduced the expression of CD36 in both cytosine-phosphate-
guanine (CpG) stimulated and unstimulated cells. It was additionally found here that the 
phagocytic index decreased complementing the lowered CD36 effect (Wu et al., 2016). 
While Rios, Gidlund, and Jancar (2011) showed that JNK inhibition reduced CD36 
expression in adherent monocytes/macrophages stimulated with oxLDL. 
These results alongside this current research seem to indicate that in certain cell lines, such 
as U937s, JNK is more responsible for the maintenance of basal CD36 levels and not for 
inducing a phosphorylation mediated down regulation event at PPARγ. This would explain 
as to why SP600125 is causing a reduction in CD36 levels when used alone, along with its 
failure to rescue 7,8-NP induced CD36 down regulation.  
4.4.2 ERK1/2 inhibition 
The inefficiency of JNK inhibition to block 7,8-NP induced CD36 down regulation shifted 
the focus to the ERK1/2 kinase whose phosphorylation of PPARγ has also been 
demonstrated to decrease the transcription of CD36 (Adams et al., 1997; Han et al., 2000). 
To explore the role of ERK1/2 in this process, the MEK inhibitor (MAPKK that precedes 
ERK) PD98059 was used. The results here showed that similar to the effect seen with JNK 
inhibition, PD98059 failed to block 7,8-NP’s down regulation of CD36 (Figure 3.4.3). Yet 
while PPARγ phosphorylation via ERK1/2 has been shown to negatively impact CD36 
transcription, the use of MEK inhibitors in other model monocyte/macrophage systems 
have additionally had contrasting results. 
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In experiments looking at THP-1 macrophages that had been stimulated with indoxyl 
suflate to take up oxLDL, upregulation of CD36, not down regulation, was inhibited via 
the use of MEK inhibitors (Cao, Fu, Wang, Jin, & Li, 2014). Cai, Lanting, and Natarajan 
(2004) again using THP-1 macrophages showed that upregulation of CD36 after binding 
to VSMCs was blocked by MEK inhibition in both bound and unbound THP-1s. While 
Rios et al. (2011) using PBMC’s showed that upregulation of CD36 after stimulation with 
oxLDL could be reduced to basal levels via incubation with MEK inhibitors.  
Similar to the results found when inhibiting JNK, the role of ERK1/2 appears to be more 
complex and is not only simply involved in the down regulation of CD36 transcription. 
Further research is required to fully identify the relationship between JNK and ERK1/2 
kinase mediated phosphorylation and CD36 transcription in U937s, and to identify at what 
level of regulation they are having their strongest effect if not at PPARγ. Or whether if the 
phosphorylation mediated transcriptional decrease model is still viable when using the 
U937 cell line.  
4.4.3 p38 inhibition 
The failure of inhibiting both kinases known to phosphorylate PPARγ in stopping 7,8-NP 
induced down regulation of CD36 shows that a MAP kinase cascade is unlikely to be the 
mechanism involved. Yet in carrying on with exploration of the kinase relationship to 
CD36, and due to the availability of its inhibitor, it was decided to additionally test the role 
of the common p38 kinase signalling pathway in this process. While p38 has not been 
demonstrated to have the ability to bind and phosphorylate PPARγ in vitro it was of interest 
to look at in this body of work due to it being role a major MAP kinase involved in cell 
signalling and with several publications having demonstrated a relationship between p38 
and PPARγ/CD36.  
The results using the specific p38 inhibitor SB202190 showed a similar effect to that seen 
when inhibiting ERK1/2 and JNK, with p38 inhibition failing to block the down regulation 
effect 7,8-NP had on CD36 (Figure 3.4.3). It was interesting to note however that when 
the U937 cell line was solely incubated SB202190 a significant decrease in CD36 
expression was observed. This type of result does not appear to be unique in the literature. 
Using primary trophoblasts Schild et al. (2006) demonstrated that p38 inhibitors decreased 
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PPARγ’s transcriptional activity while having no effect on PPARγ expression. While 
research using 3T3-L1 fibroblasts showed that PPARγ activity is diminished in the 
presence of p38 inhibitors and additionally prevented lipid accumulation (Engelman, 
Lisanti, & Scherer, 1998), indicative of an effect of PPARγ target genes. Specifically in 
relation to CD36 Wu et al. (2016) showed that p38 inhibition reduced the expression of 
CD36 in both cytosine-phosphate-guanine (CpG) stimulated macrophages in which CD36 
expression was enhanced, along with unstimulated cells. While Zhao et al. (2002) found 
that using a p38 inhibitor blocked foam cell formation in J774 cells exposed to oxLDL by 
reducing CD36 expression. 
These results alongside the current research show that while p38 may not be 
phosphorylating PPARγ it is having a level of effect in relation to CD36, or could be 
interacting with PPARγ at an as yet unknown site. A possible explanation for this may be 
instead be related to PPARγ stabilization. Puigserver et al. (2001) identified a relationship 
between p38 and PPARγ in which cytokine activation of p38 resulted in the activation and 
stabilization of PPARγ coactivator-1. Prevention of this would necessarily decrease the 
ability of PPARγ to bind its DNA consensus sites and subsequently inhibit target gene 
transcription, including that of CD36. 
4.4.4 NF-κB inhibition 
As shown in the experiments looking at JNK, ERK1/2 and p38 the use of MAP kinase 
inhibitors consistently failed to block 7,8-NP’s down regulation effect of CD36. It was next 
decided in carrying on with the theme of looking at cellular signalling, and due to the 
inhibitors being available in the Free Racial Biology Laboratory, to explore the effect of 
NF-κB inhibition on 7,8-NP induced down regulation.  
NF-κB has been shown to play a role in both cellular inflammatory response and 
atherosclerosis (Pamukcu, Lip, & Shantsila, 2011). Under unstimulated conditions NF-κB 
exists in the cellular cytoplasm in an inhibited sate via interaction with iKB but can become 
activated upon stimulation with stress, cytokines, free radicals and bacterial antigens. After 
activation NF-κB disassociates with iKB and can translocate to the nucleus where it can 
induce the transcription of a number of genes including those involved in the production of 
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cytokines, adhesion molecules chemokines and matrix metalloproteinases (Struzik, Szulc-
Dabrowska, & Niemialtowski, 2014).  
The results of this current research showed NF-κB inhibition via the specific inhibitor BAY 
11-7082 failed to block 7,8-NP induced down regulation on CD36, and similar to JNK and 
p38, NF-κB inhibition itself was sufficient to decrease CD36 levels (Figure 3.4.7). The 
lack of an amelioratory effect was not overly surprising as NF-κB’s major role in lipid 
metabolism is related more to cholesterol efflux than influx (Tian & Tang, 2014; Xue et 
al., 2010; Yu et al., 2011; Zhao et al., 2014), with the relationship between NF-κB and 
CD36 being more complex with contradictory experimental results. Masndose et al. 
showed that after Atorvastatin therapy, CD36 down regulation was associated with a 
significant reduction in the NF-κB levels of circulating monocytes in patients with Type II 
diabetes (Mandosi et al., 2010). Similarly a study showed that demethylated metabolites 
derived from nobiletin prevented NF-κB activity which was associated with reduced CD36 
expression and cholestol uptake in the THP-1 cell line (Eguchi, Murakami, Li, Ho, & 
Ohigashi, 2007). Ferreira et al. (2007) et al. found an opposite effect in that macrophages 
with inactivated NF-κB were associated with an increase in CD36 mRNA and Ye, Jiang, 
Guo, Clark, and Gao (2013) showed that over expression of NF-κB p65 (a subunit of NF-
κB transcription complex) resulted in reduced CD36 levels and lipid content. 
The results of the current experimental work aligns more with the first series of 
observations in which NF-κB inhibition was associated with a significant decrease in CD36 
levels. This is similar to results found when using other monocytes but dissimilar to the 
macrophage experiments. It is possible that the differentiation state may have some level 
of impact on the effect of NF-κB in relation to CD36. Although importantly in relation to 
this thesis these results rule out a NF-κB mediated pathway for 7,8-NP’s effect on CD36. 
4.5 A different mechanism of effect  
The inability of MAP kinase inhibitors to block 7,8-NPs effect on CD36 indicates that the 
down regulation is not occurring via a kinase pathway, or alternatively via the NF-κB 
pathway. This necessarily shifts the focus to a different mechanism of effect.  
One possible pathway may involve a specific antioxidant activity of 7,8-NP. A wide variety 
of research has been published exploring the effects of antioxidants on CD36 using both 
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cell and animal models. Using PMBC cells Dedoussis et al. (2004) demonstrated an effect 
with an antioxidant extract derived from Pistacia lentiscus. The extract restored 
Glutathione (GSH) levels, along with down-regulating CD36 expression including at the 
mRNA level in cells exposed to oxLDL. Using differentiated T3-L1 adipocytes it was 
found that the antioxidant molecules Oleuropein and Hydroxytyrosol exhibited a 
concentration dependent decrease in both PPARγ and CD36 levels (Drira, Chen, & 
Sakamoto, 2011) while treatment of SMCs and HL-60 macrophages with α-tocopherol 
down regulated CD36 expression (Ricciarelli et al., 2000). Paeonol, a potent antioxidant 
which has been shown to possess athero‑protective activity, significantly reduces 
intracellular lipid accumulation in macrophages along with inhibiting the mRNA and 
protein expression of CD36.  In animal models Podszun et al. (2014) found that when 
Guinea Pigs on a high fat diet were supplemented with the antioxidant α-tocopherol or 
Atorvastatin CD36 levels were reduced to that of control. Likewise a study looking at the 
kidneys of rats undergoing chronic renal failure found that those supplemented with the 
antioxidant Niacin reduced the relative optical density of CD36 in renal tissue to lower than 
that of healthy controls (Cho, Kim, Kamanna, & Vaziri, 2010). 
However a general antioxidant effect is unlikely to be responsible in terms of CD36 
regulation as the down regulation seen is not universal. Ricciarelli et al. (2000) who 
demonstrated the effect of α-tocopherol found no effect with either β-tocopherol or 
Procubul. While the antioxidant curcumin which lowered oxLDL induced cholesterol 
accumulation in macrophages, had no effect on CD36 (Zhao et al., 2012). 
As a general antioxidant effect is unlikely, 7,8-NP needs to be able to act upon a specific 
pathway related to CD36 transcription. Alongside MAP kinase mediated phosphorylation, 
PPARγ function can also be regulated by ligand binding. Of particular note is redox-
regulation with several oxidised ligands having been shown to bind and activate PPARγ. 
The oxidised lipid 15-deoxy-Δ12,14-PGJ2 has been shown to act as a ligand (Forman et 
al., 1995), along with other polyunsaturated omega-6 fatty acid metabolites (Kliewer et al., 
1997). 9- Hydroxyoctadecadienoic acid (9-HODE), 13-(HODE) and 15(s)-HETE have also 
been shown to bind and promote PPARγ activation (Lenz et al., 1990; Nagy, Tontonoz, 
Alvarez, Chen, & Evans, 1998). Lipooxygenase (LXO) activity within the cell is 
responsible for the oxidation of phospholipids to HETES and HODES (Rosolowsky & 
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Campbell, 1996; Yuan et al., 2010). As 7,8-NP is produced by the macrophage cell it is 
possible that 7,8-NP is inhibiting LXO activity here, thus stopping oxidised ligand 
formation and their interaction with PPARγ. This would explain the lack of effect of other 
antioxidants which may not necessarily be present in the appropriate location to inhibit this 
process.  
7,8-NP may also be acting on a more specific pathway such as the JAK/STAT pathway. 
Activated STAT1 can form homodimers which when translocated to the nucleus will bind 
consensus DNA γ-activated sites which can lead to the transcription of CD36 (O'Shea et 
al., 2002; Ramana et al., 2002). Interaction of STAT1 with PPARγ requires it to become 
actytelated, but not phosphorylated. Acetylation requires p300 activation which in turn 
requires Syk2 and Pyk2 stimulation mediated by xanthine oxidase (XO) and importantly 
NADPH oxidise (NOX) ROS production. It is possible that 7,8-NPs mechanism of action 
involves radical scavenging of the ROS generated by NOX and XO and in so blocking 
STAT1 activation by this mechanism.  
4.6 Incomplete down regulation 
It was of note that during this research that although down regulation of CD36 was able to 
be constantly observed and mediated via a range of conditions, complete removal of the 
CD36 band was not. The maximum average level of down regulation was consistently 
around ~40% of control. This result was not entirely unexpected as the processing of CD36 
is such that it goes through several modification steps before it is able to be transferred from 
the Golgi apparatus to the cell surface. It is possible that the time allowed in the current 
experimentation was not enough to account for CD36 already synthesised but not yet fully 
transported. As shown in the cycloheximide experiment the half-life of detected CD36 was 
observed at being around 6 hours. This would indicate that the majority of the detected 
CD36 would have been ubiquitinated and degraded by the end of 24 hours. However 
incompletely transported CD36 would have been the least likely to be affected by this 
process and it is possible that the CD36 detected at the end of the down regulation 
experiments is a result of this residual CD36.  
Another possible explanation for the lack of complete down regulation is the complexity 
of the PPARγ transcription system.  PPARγ itself contains kinase and ligand binding sites, 
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both of which are inter-related (Han et al., 2000), while also forming a heterodimer with 
RXR which itself will bind ligands (Lengqvist et al., 2004). It may be that 7,8-NP is only 
targeting one part of this system in an antagonistic way, while having limited interaction 
with the other components. This would allow for the continued interaction between the 
PPARγ:RXR heterodimer and additional agonists that compete with 7,8-NP induced down 
regulation, lessening its effect.  
4.7 Future research 
Future research will need to explore additional mechanistic pathways to explain how 7,8-
NP down regulates CD36. One obvious system to investigate would be the involvement of 
oxidised ligands and redox regulation in PPARγ activation and CD36 transcription. This 
would be able to be achieved by co-incubating U937 cells with synthetic PPARγ ligands 
alongside 7,8-NP. If 7,8-NP is having its effect via preventing the oxidation of fatty acids, 
the addition of further ligands at the right concentrations should be able to overcome this 
effect. The role of ROS in STAT mediated CD36 regulation and the effect of 7,8-NP here 
should also be explored. Of particular note would be the examination of the role that 15(S)-
HETE plays in the activation of NADPH oxidase and whether 7,8-NP could prevent the 
subsequent ROS production leading to CD36 transcription. It would also be of interest to 
explore the mechanistic pathway of 7,8-NP induced down regulation in other cells lines 
apart from U937s, as the method of down regulation here would not necessarily be 
universal. The levels of PPARγ and phosphorylated PPARγ in U937s after treatment should 
also be examined to fully confirm the kinase inhibitor studies in this research. 
4.8 Summary 
This research confirms that 7,8-NP down regulates CD36 in a time and concentration 
dependant manner in the U937 cell line. It was also shown that PPARγ is under 
transcriptional control of CD36 in the U937 cell line and that 7,8-NP is having its effect at 
the transcriptional level, and not by enhancing protein degradation. In relation to the 
mechanistic pathway, 7,8-NP is not down regulating CD36 via a MAP kinase cascade. Nor 
is it working via an NF-κB signalling pathway. Further research into the mechanism of 7,8-
NP induced CD36 down regulation is required, including investigating the role that 
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